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Type 2 diabetes is a growing epidemic that has been accompanied by a 
similarly drastic increase in obesity. Its occurrence is associated with β-cell 
dysfunction, decreased β-cell mass, and insulin and leptin resistance. An 
increasing body of evidence suggests that endoplasmic reticulum (ER) stress may 
play an important role in the development of diabetes. The accumulation of 
terminally misfolded proteins in the ER results in ER stress if the folding capacity 
and degradation within the ER is insufficient. In this condition of disequilibrium, 
the unfolded protein response (UPR) is activated to restore ER homeostasis. The 
mouse and human suppressor-enhancer-lin12-1-like (Sel1L) gene encodes a 
structurally complex protein with high expression in the adult pancreas and 
central nervous system. Evidence from in vitro studies and lower organisms 
implicates SEL1L as a crucial factor in endoplasmic reticulum-associated 
degradation (ERAD) of unfolded or misfolded proteins, a pathway of the UPR. 
However, the physiological role of SEL1L in the whole organism remains elusive. 
The Long lab has generated the first mouse model featuring the global deletion 
of Sel1L. Mice homozygous for this hypomorphic allele are early embryonic 
lethal. Our embryological and in vitro data indicated that the absence of Sel1L led 
to changes in organelle morphology, the initiation of apoptotic pathways, 
decreased cell viability, and defective cellular degradation. Due to the embryonic 
lethality of the homozygous Sel1L mutant mice, the viable heterozygote (Sel1L+/-) 
mice were used to understand the contribution of ERAD to the development of 
obesity-induced diabetes. We found that mice heterozygous for Sel1L are 
predisposed to high-fat diet-induced hyperglycermia, glucose intolerance, 
reduced β-cell mass, and impaired insulin secretion in comparison to wild-type 
mice. Finally, to further investigate the tissue-specific roles of SEL1L, we 
generated mice with the conditional deletion of Se1lL in β-cells and hypothalamic 
neurons. Mice with RIP-Cre-mediated deletion of Sel1L (mutant) showed 
elevated blood glucose levels in comparison to control mice by 2 weeks of age. 
Additionally, mutant mice exhibit progressive glucose intolerance and severely 
defective glucose-stimulated insulin secretion. In adulthood, mutant mice 
develop hyperphagic obesity and peripheral leptin and insulin resistance. 
Altogether, these deviances in glucose and energy homeostasis at the level of the 
β-cell and hypothalamic neuron, respectively, are attributed to ER stress in the 
absence of SEL1L. These data collectively provide compelling evidence for the 
causal role of ER stress in the manifestation of Type 2 diabetes. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1  An Overview of Type 2 Diabetes 
The World Health Organization predicts that 346 million people 
worldwide are currently living with diabetes. This number is expected to double 
by 2030, indicating that this disease is reaching global epidemic proportions (1). 
The multiple complications that arise from the disease can be severe and fatal, 
and include heart disease and stroke, high blood pressure, kidney disease, 
retinopathy, and neuropathy.  
Diabetes mellitus, or simply diabetes, is the condition defined by elevated 
blood glucose levels (hyperglycemia). Therefore, this disorder originates in the 
pancreas, a glandular organ that has integral exocrine and endocrine functions in 
vertebrates. The islets of Langerhans are responsible for mediating the endocrine 
functions of the pancreas, and there are approximately one million of these cell 
clusters in the human pancreas (2). The β-cell is one of four cell types in the islets, 
and its most notable function is the production and secretion of insulin, an 
anabolic hormone, in response to elevated blood glucose. Insulin stimulates 
glucose uptake and promotes glycogen synthesis in tissues to maintain normal 
blood glucose levels. While Type 1 diabetes (T1D) is characterized by the specific 
destruction of β-cells and a consequent lack of insulin production, Type 2 
diabetes (T2D) is associated with a reduced ability of β-cells to secrete enough 
insulin and a failure of peripheral tissues to respond to insulin. Although T1D 
and T2D are the most common forms, cases of gestational diabetes, monogenic 
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diabetes, and other rare forms do exist. It is estimated that T2D accounts for 90% 
of people with diabetes worldwide (3).  
Therefore, T2D manifests from two major defects: insulin resistance and a 
progressive decline in β-cell function. Insulin resistance is commonly observed 
during our normal life cycles, in situations of pregnancy, puberty, and with 
aging. Healthy β-cells are able to adapt to this resistance through changes in 
functional responsiveness of the cell and also in total β-cell mass (4). Through 
adjusting these two parameters, many insulin-resistant individuals do not 
ultimately develop hyperglycemia. When there is an inherent inability of the β-
cells to initiate this adaptive response (i.e. the secretory capacity deteriorates), 
normal glucose tolerance cannot be maintained. The result is glucose intolerance 
and increased fasting glucose levels, leading to T2D. Aside from defects in 
insulin secretion and action, loss of β-cell mass and an insulin deficiency also 
contribute to the pathogenesis of T2D. Postmortem studies have shown T2 
diabetic patients have reduced β-cell mass (up to 63%) and increased β-cell 
apoptosis rates (5). Apoptosis is likely to play a critical role in the reduction of β-
cell mass seen in T2D, but the specific mechanisms by which this programmed 
cell death occurs has yet to be determined.    
Research on the pathophysiology of T2D has evolved from focusing on the 
endocrine pancreas to placing more emphasis on a network of organs affected by 
this metabolic state. These organs include adipose tissue, the brain, the liver, and 
skeletal muscle. This complex integration of factors contributing to the 
progression of T2D is summarized in Figure 1.1: 
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Figure 1.1: The Pathogenesis of Type 2 Diabetes (T2D). The 
manifestation of T2D involves several key organs, including the pancreas, brain, 
adipose tissue, liver and skeletal muscle. In the pancreas, β-cell dysfunction and 
β-cell loss cause a decrease in circulating insulin, resulting in elevated plasma 
glucose levels. In the brain, leptin-sensitive hypothalamic neurons are no longer 
responsive to the anorexigenic effects of leptin, causing an increase in food intake  
and a decrease in energy expenditure. Over time, this results in an expansion of 
adipose tissue and obesity, which is associated with insulin resistance. The 
failure of peripheral tissues, such as liver and skeletal muscle, to respond to 
insulin also exacerbates glucose intolerance in T2D.  
 
This change in paradigm can be attributed to the correlation between T2D 
and metabolic syndrome. The metabolic syndrome is an insulin-resistant state 
that is defined by obesity, elevated triglycerides, decreased high-density 
lipoprotein cholesterol, hypertension, and impaired fasting glucose (6). Together, 
these factors confer an increased risk for both cardiovascular disease and T2D (6).   
About 80% of patients with T2D are considered overweight or obese (having a 
body mass index, or BMI, over 25) (3). In obese individuals, the increased 
deposition of adipose tissue leads to elevated levels of its secretory products, 
including non-esterified fatty acids, glycerol, pro-inflammatory cytokines and 
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hormones. These products have been shown to contribute to the development of 
insulin resistance in not only adipose tissue, but also in the liver and skeletal 
muscle (7). 
  Adipose tissue also produces leptin, a hormone that has potent effects on 
energy balance and is therefore a key component in the pathogenesis of T2D (8). 
These effects are mainly mediated specifically by leptin binding its receptors in 
the arcuate nucleus (ARC) of the hypothalamus, although leptin receptors exist 
on other neuronal populations (9). There, it influences two sets of neurons that 
act as sensors of whole-body energy status, and initiates signals to maintain 
energy stores at a constant level. Neurons that co-express agouti-related peptide 
(AGRP) and neuropeptide Y (NPY) are inhibited by leptin and insulin, while 
neurons that co-express pre-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART) are stimulated by leptin and insulin 
(10-12). Both neurons synapse onto second-order neurons in other regions of the 
hypothalamus to exert their effects. These regions include the paraventricular 
nucleus (PVN), ventromedial hypothalamus (VMH), and lateral hypothalamus. 
Ultimately, leptin stimulation decreases food intake and weight gain, while 
leptin inhibition has the opposite outcomes. Many of the anorexigenic effects of 
leptin are mediated by POMC processing in the ARC (13). POMC undergoes 
significant posttranslational modifications to give rise to a range of biologically 
active peptides, including !-melanocyte stimulating hormone (!-MSH). !-MSH 
is an agonist of the melanocortin-4 receptor (MC4R), which is prevalently 
expressed in the PVN, while AGRP is an antagonist of this receptor (14). The 
downstream targets of MC4R signaling include brain-derived neurotrophic 
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factor (BDNF), corticotropin-releasing hormone (CRH), thyrotropin-releasing 
hormone (TRH), melanin-concentrating hormone (MCH), and orexins (15). 
Mice lacking the leptin gene, known as ob/ob mice, are profoundly obese 
due to hyperphagia. The ob/ob mouse is a powerful and common animal model 
for T2D. Mutations in the human leptin gene have been identified as a cause of 
obesity, but occur infrequently (16). About 5% of severe human obesity is due to 
a mutation of the MC4R gene (17). Mutations in the POMC gene, which therefore 
prevents the production of !-MSH, produce severe human obesity as well (18). 
MC4R and POMC mutations result in a syndrome of hyperphagic obesity in 
humans, indicating that the central melanocortin pathway is mainly involved in 
the control of food intake. This provides some insight into the genetic basis of 
central leptin resistance. Obese individuals commonly exhibit leptin resistance, 
with high circulating levels of leptin due to increased adiposity, yet no 
anorexigenic response to the leptin in the brain (19). The result is the failure to 
produce a feeling of satiety after eating, leading to increased food intake and 
exacerbated adiposity.  
The precise mechanisms linking increased adiposity to insulin resistance 
are unknown, but proinflammatory cytokines such as tumor necrosis factor 
alpha (TNF!) and interleukins-1 and -6 have been shown to disrupt insulin 
action in adipocytes, myocytes, and hepatocytes (7). Insulin resistance involving 
both the liver and muscle is a distinctive feature of T2 diabetic individuals. The 
resulting glucose intolerance is further exacerbated by an increase in hepatic 
glucose production. This accelerated rate of hepatic glucose output is a major 
determinant of the elevated fasting plasma glucose concentration in T2D (20).  
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Altogether, hyperglycemia due to β-cell dysfunction and peripheral 
insulin resistance defines T2D. However, due to its complexity, the pathogenesis 
of this disease is still poorly understood. There is compelling genetic, 
biochemical and clinical evidence for genetic as well as environmental factors 
that contribute to its development. The genetic basis includes genes that confer 
susceptibility to impaired β-cell secretion, decreased β-cell viability, and insulin 
and leptin resistance (both peripheral and central). The environmental basis 
includes poor nutrition and decreased physical activity. Despite this extensive 
research, T2D is defined as a multifactorial disease with unknown origins. 
Accumulating evidence points to an intracellular stress localized at the 
endoplasmic reticulum (ER) as a major contributor to the manifestation of T2D. 
This is justified by the physiological challenge presented to the organs involved 
in T2D, all of which have a high capacity for secretory protein synthesis. The 
unfolded protein response (UPR) is the adaptive response of the mammalian cell 
to maintain homeostasis within the ER and prevent this intracellular stress. 
Therefore, failure of the UPR could potentially explain the transition from 
physiology to pathology in the context of T2D. 
 
1.2  The Unfolded Protein Response 
The ER is a highly versatile organelle with a central role in lipid and 
protein biosynthesis (21). The lumen provides a specialized environment that 
facilitates the post-translational modifications and folding of secreted proteins. 
These post-translational modifications include lipidation, hydroxylation, and 
oligomerization, but the most common modifications amongst the secreted 
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proteins are N-linked glycosylation and disulfide oxidation (22). Proteins that 
have attained their native conformation are cleared for exit from the ER and 
continue through the secretory pathway. Improperly folded proteins, however, 
are either retained to complete additional folding cycles or are targeted for 
degradation in a process referred to as “quality control” (23). This will be 
discussed in further detail later. 
 When there is disequilibrium between ER protein load and the folding 
capacity of the machinery, ER stress is the result. Some physiological causes of 
ER stress include hypoxia, exposure to environmental and experimental toxins, 
excess nutrients, and genetic mutations that impede proper folding of proteins 
(24). ER stress elicits the UPR, which alleviates ER stress, restores ER 
homeostasis, and prevents cell death.  
There are three central signaling pathways in the UPR, depicted in Figure 
1.2, and each is regulated by an individual transmembrane ER stress “sensor.”  
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Figure 1.2: The Unfolded Protein Response (UPR). The UPR is the cell’s 
adaptive response to ER stress. With an increase in misfolded proteins in 
the ER lumen, the chaperone BiP dissociates from three ER 
transmembrane sensors of ER stress: PERK, IRE1α, and ATF6. This 
dissociation activates three signaling pathways, each producing a distinct 
transcription factor that translocates to the nucleus to induce the 
transcription of various UPR genes. Altogether, the upregulation of UPR 
genes will ameliorate ER stress. Adapted from Figure 1 of (25). 
 
These sensors are IRE1α, PERK, and ATF6!. Each pathway has an ultimate 
downstream effecter that goes on to mediate the induction of ER stress response 
element genes (ERSEs) (26). The molecular chaperone GRP78, also known as BiP, 
remains associated with the luminal domains of IRE1α and PERK in their 
inactive state. Upon ER stress, unfolded proteins in the ER lumen necessitate 
GRP78 dissociation, resulting in oligomerization and autophosphorylation of 
IRE1α and PERK (27). ATF6! is also regulated by GRP78, and GRP78 
dissociation from the sensor causes ATF6 to be transported to the Golgi 
apparatus and become activated (28). Briefly, IRE1α splices XBP1 mRNA 
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(XBP1s). The spliced XBP1 mRNA encodes a basic leucine zipper transcription 
factor that upregulates UPR target genes (29). Activated PERK directly 
phosphorylates the Ser51 residue of !-subunit of eukaryotic initiation factor 2 
(eIF2α). This in turn inhibits protein translation by reducing the formation of 
ribosomal initiation complexes and recognition of AUG initiation codons (30). It 
simultaneously increases the translation of the transcription factor ATF4, which 
goes on to bind ERSEs. ATF6! transits to the Golgi where it is protealytically 
cleaved. The cleaved ATF6 transcription factor translocates to the nucleus to 
mediate UPR effects (31). 
Ultimately, there are four distinct processes that result from the induction 
of UPR genes (Figure 1.3): an increase in the folding capacity of the cell through 
transcriptional activation of ER chaperones, reduction of the biosynthetic load by 
translational attenuation, degradation of misfolded proteins by ER-associated 
degradation (ERAD), and apoptosis (22).  
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Figure 1.3: Outcomes of the Unfolded Protein Response. The adaptive 
outcomes of the UPR include transcriptional activation of chaperones 
(mediated by IRE1 and ATF6), translational attenuation (mediated by 
PERK), and ER-associated degradation (ERAD, mediated by IRE1 and 
ATF6). If these outcomes fail to restore ER homeostasis, apoptotic 
pathways are activated. 
 
Apoptosis is initiated in cells as the last resort when the UPR cannot successfully 
adapt to the stress. Apoptosis is a tightly regulated and controlled process that 
involves specific biochemical and morphological changes, including cell 
membrane blebbing, formation of apoptotic bodies, chromatin condensation, and 
DNA fragmentation (32). Two central pathways are known to mediate apoptosis: 
the extrinsic pathway, which uses cell surface death receptors, and the intrinsic 
pathway, which utilizes the mitochondria and endoplasmic reticulum (part of 
the UPR). The UPR signals that are involved in facilitating the intrinsic pathway 
originate from IRE1α and PERK dimerization during ER stress. Collectively, 
C/EBP homologous protein transcription factor (CHOP), c-Jun NH2-terminal 
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kinase (JNK), and caspases have been implicated in ER stress-related cell death 
(26). Downstream activation of CHOP and JNK mediates cell death through 
regulation of the B-cell lymphoma-2 (BCL2) family of proteins. Under normal 
conditions, the pro-apoptotic Bax and Bak are kept inactive by interaction with 
BCL2 both on the mitochondrial and ER membranes (33). Bim, another member 
of the BCL2 family, is inhibited by binding to cytoskeletal dynein. Both JNK and 
CHOP eliminate the anti-apoptotic effect of BCL2; CHOP blocks expression of 
BCL2, whereas JNK phosphorylates it. JNK also phosphorylates Bim, which 
leads to its release from the cytoskeleton and to its activation (34). Together, 
these changes allow activation of Bax and Bak, transmission of the signal from 
the ER to the mitochondria, alternations in mitochondrial membrane potential, 
and execution of death. Caspases are activated possibly on the ER membrane 
itself, as well as in the apoptosome (a protein complex formed once apoptosis is 
initiated), after transmission of the death signal to mitochondria and the release 
of cytochrome c (35). 
 
1.3  ER Stress in Tissues Associated with T2D 
The UPR is activated in many of the tissues and cell types that are central 
to the pathogenesis of diabetes and obesity. In vivo and in vitro evidence from 
models that recapitulate T2D confirms the presence of ER stress in the liver, 
adipose tissue, hypothalamus and β-cells, as summarized below.  
 
 
 
  12 
1.3.1  Liver and Adipose Tissue 
The liver is one of the most productive secretory organs in the body. Its 
secretory products include bile acids, lipoproteins, and all major plasma proteins 
including albumin, fibrinogen, and blood clotting factors. Therefore, the UPR has 
an important role in maintaining ER homeostasis for proper liver function. This 
is evidenced by the fact that physiological ER stress is observed in the liver of 
rodents that are re-fed after fasting; but this diminishes within a few hours (36). 
Chronic hepatic ER stress, however, is seen in both obese mice and humans (37). 
In addition to insulin resistance, obesity is also associated with hepatic steatosis 
(the accumulation of lipids within the hepatocyte).  An increasing body of 
evidence supports the link between steatosis and ER stress in the liver, thus 
pointing to an important role for the UPR in lipid metabolism. Steatosis in ob/ob 
mice has been associated with an accumulation of the transcription factors 
SREBP1c and SREBP2, which promote lipogenesis and cholesterol biosynthesis 
(38). ER stress causes this accumulation by excessive proteolytic cleavage and 
activation of the transcription factors. This was further confirmed by the hepatic 
adenoviral delivery of GRP78, which decreases SREBP1c activation, triglyceride 
and cholesterol contents, and improves insulin signaling in the liver (38). Hepatic 
ER stress also reduces the secretion of apolipoprotein B100 (apoB100), which is 
required for very-low-density lipoprotein (VLDL) assembly and potentially 
protects against steatosis (39).  
Transcription factors such as XBP1 and CREBH (a hepatocyte-specific 
form of CREB) have been identified as key regulators of gluconeogenic enzymes 
in the liver. XBP1s can interact directly with FOXO1, which plays an important 
role in gluconeogenesis and glycogenolysis in the insulin pathway. FOXO1 can 
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be targeted to the proteasome by XBP1s, thereby inhibiting gluconeogenesis and 
consequently hepatic glucose output (40).  The CREBH transcription factor, 
which is cleaved by the same process as ATF6 in conditions of ER stress, can also 
activate the transcription of gluconeogenic genes (41). RNAi-mediated 
knockdown of CREBH in diabetic mice can improve fasting hyperglycemia due 
to decreased glucose production in the liver (42). 
Obesity also leads to chronic ER stress in adipose tissue. In both dietary 
(high-fat diet, or HFD) and genetic (leptin-deficient) mouse models of obesity, 
the adipose tissues show elevated expression of several ER stress markers in 
comparison to their lean counterparts (37).  This elevation in biochemical 
markers has also been seen in the fat depots of obese, insulin-resistant 
individuals versus non-obese counterparts (43). Obesity is particularly associated 
with IRE1! and PERK activation, JNK1 activation, and upregulation of XBP1s 
and chaperone expression in adipose tissue. The increased expression of IRE1- 
and ATF6-dependent chaperones in adipocytes in vivo is mimicked in vitro by 
adipocyte exposure to lipopolysaccharide, saturated free fatty acids (FFAs), or 
high glucose (44). The heightened inflammatory response observed in adipose 
tissue of obese individuals is also associated with ER stress. FFA-induced ER 
stress in adipocytes is proinflammatory via PERK-dependent activation of IKK", 
an important regulator of the expression of inflammatory genes (45).   
 
1.3.2  Hypothalamus 
 The hypothalamus is critical in the development of T2D because it is the 
site of central leptin and insulin resistance (46). The failure of hypothalamic 
neurons to respond to these anorexigenic hormones appears to involve a 
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combination of ER stress and inflammation. HFD-fed mice as well as ob/ob mice 
show increased ER stress in their hypothalami in comparison to lean controls 
(47). ER stress in the hypothalamus causes leptin resistance in lean mice, as 
assessed by a decrease in downstream markers of leptin signaling such as STAT3 
phophorylation and neuropeptide expression. In accordance with this, chemical 
chaperones such a 4-phenylbutyric acid (4-PBA) and tauroursodeoxycholic acid 
(TUDCA), are able to decrease ER stress and improve leptin signaling in vitro 
and in vivo (47).  
 A HFD in rodents can also induce inflammatory protein expression in the 
hypothalamus (48).  Administration of long-chain saturated fatty acids through 
an intracerebroventricular (ICV) route reveals that toll-like receptor (TLR) 
signaling is the main event that causes increased cytokine expression and ER 
stress in the brain. TLRs play a critical role in the innate immune response and 
participate in the first line of defense against pathogens (49). Ablation of TLR4 
through genetic and pharmacological approaches leads to protection from HFD-
induced ER stress, cytokine expression, body mass gain, and leptin resistance. 
Accordingly, overnutrition caused by a HFD has also been shown to activate 
NF#B, or nuclear factor kappa-light-chain-enhancer of activated B cells (50). 
NF#B is a downstream transcription factor in TLR signaling, and is immediately 
regulated by I#B kinase (IKK). The activation of the IKK/NF#B pathway by 
HFD-feeding was blocked with TUDCA infusion into the third ventricle (ICV) of 
mice. This finding suggests that overnutrition-induced NF#B activation in the 
hypothalamus is, at least partly, mediated by ER stress. Furthermore, IKK/NF#B 
activation contributes to central leptin and insulin resistance. The proposed 
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mechanism for this association is that NF#B promotes the expression of Socs3, an 
inhibitor of leptin and insulin signaling.   
 This evidence points to developing new strategies to reduce inflammation 
and ER stress in the hypothalamus of obese subjects, for the purpose of 
overcoming central leptin and insulin resistance. Exercise has been shown to 
increase the expression of interleukin-6 (IL-6) in obese rodents, a cytokine that 
has the potential to be anti-inflammatory (51). This natural anti-inflammatory 
response can reduce IKK/NF#B activation and ER stress, thus improving leptin 
and insulin sensitivity in the hypothalamus. 
 The effects of ER stress in the hypothalamus are not limited to immediate 
leptin and insulin signaling. Several obesity-linked variants of MC4R are 
retained in the ER of immortalized neurons, causing an increase in the 
expression of ER chaperones, increased ER-associated degradation, and 
decreased expression of the receptor at the plasma membrane (52). Here, ER 
stress is caused by a misfolded protein (MC4R variant) and affecting its 
trafficking and ultimately its localization. Treatment with 4-PBA restores the 
receptor to the cell surface and is also able to rescue the function of one variant. 
 
1.3.3  !-cells  
Although there is impaired insulin sensitivity in obese individuals, 
diabetes ensues only when insulin resistance coexists with insulin deficiency. In 
order to execute its normal function of insulin secretion in response to nutrient 
signals, namely glucose stimulation, the β-cell necessitates exquisite regulation of 
insulin production and release. Therefore, any increase in insulin secretion 
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results in a corresponding increase in proinsulin biosynthesis to maintain readily 
available pools of insulin within secretory vesicles (53). Insulin is translated as a 
preproinsulin molecule, which translocates into the ER lumen and undergoes 
signal peptide cleavage to yield proinsulin. Proinsulin is subjected to a folding 
process that involves disulfide bond formation (54). Once the proinsulin 
molecule has achieved its native alignment and conformation, it is delivered to 
the Golgi apparatus and subsequently packaged into secretory vesicles. Here, 
proinsulin is cleaved by a series of endopeptidases to give rise to mature insulin 
(55). Two likely conditions would result in disequilibrium of ER protein load and 
processing capacity, leading to β-cell ER stress. First, the state of insulin 
resistance presents a situation of biosynthetic overload to the β-cell due to the 
adaptive response mentioned previously. Second, genetic mutations in the 
insulin gene could also generate an ER imbalance. If the ER homeostasis is 
disrupted, insulin will not be effectively released, and β-cell dysfunction arises. 
In humans, seven mutations in the insulin gene, which disrupt proper 
disulfide bond formation and proinsulin folding in the ER, have been shown to 
cause neonatal diabetes (56). The Akita mouse model recapitulates this diabetic 
state, as these mice are heterozygous for a mutation in the insulin-2 gene (57). 
The Akita mouse is characterized by hyperglycemia, decreased insulin secretion, 
and progressive apoptosis of β-cells over time. Electron microscopy of islets from 
these mice reveals distention of the ER lumen, indicating the misfolded 
proinsulin is retained in the ER and is likely causing the metabolic phenotype 
(58). Not surprisingly, several mutations in UPR genes are associated with 
young-onset diabetes, including WFS1 (an ER transmembrane protein) in 
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Wolfram syndrome and EIF2AK3 (encoding PERK) in Wollcott-Rallison 
syndrome (59, 60).  
Global and tissue-specific knockouts of PERK in mice have shown that 
PERK is of particular relevance for the fetal and early neonatal development of β-
cell mass and function (61). This pathway is also important in the translational 
control of insulin. Mice homozygous for a Ser51Ala substitution in eIF2", 
precluding its phosphorylation by PERK or other kinases, die of hypoglycemia 
within hours after birth because of defective gluconeogenesis. The pancreata 
from these mice exhibit β-cell defects and insulin depletion at late embryonic and 
neonatal stages (62). Conditional expression of homozygous Ser51Ala mutant 
eIF2! in β-cells causes a severe diabetic phenotype due to unregulated proinsulin 
translation. The β-cells also have defective intracellular trafficking of ER cargo 
proteins and increased oxidative damage, leading to massive β-cell apoptosis 
(63). IRE1 activation promotes insulin mRNA degradation in β-cells exposed to 
chronic high glucose levels, providing immediate translational relief to the ER 
(64). Over time, however, this suppression of insulin biosynthesis leads to β-cell 
dysfunction(65). Similarly, ATF6 activation inhibits insulin promoter activity by 
downregulating key transcription factors that affect insulin gene expression (66).  
 There are multiple sources of ER stress in human T2D. The β-cell secretes 
another product in addition to insulin, islet amyloid polypeptide (IAPP). Also 
known as amylin, IAPP is also expressed in β-cells, and is trafficked through the 
insulin secretory pathway and co-secreted with insulin (67). The 37-amino acid 
residue peptide in humans (hIAPP) has the propensity to form amyloid, or 
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abnormal extracellular deposits of protein, in the islets (68). In T2D, insulin 
resistance disproportionately increases hIAPP compared with insulin expression. 
Postmortem analysis revealed that more than 90% of T2D patients have hIAPP 
amyloid in their islets, and the presence of amyloid was associated with β-cell 
death (69). The cytotoxicity of hIAPP is the result of structures that act 
intracellularly to induce β-cell apoptosis, and ER stress is speculated to mediate 
this apoptosis (70).  
 As previously elaborated on, obesity and a diet high in fat are major risk 
factors for the development of diabetes. Two leading causes of obesity are over-
consumption and the intake of high-fat and refined sugary foods. Palmitate (a 
saturated fatty acid) induces β-cell ER stress due to rapid degradation of 
carboxypeptidase E and alteration of β-cell calcium influxes. These changes 
ultimately disrupt the folding and maturation of proinsulin (71). The mammalian 
target of rapamycin (mTOR) operates as an important transducer of ER stress in 
β-cells by modulating the synthesis of IRE1α and JNK activity (72). A recent 
discovery implicates that palmitate treatment of clonal β-cells hampers ER to 
Golgi protein trafficking via production of ceramides, leading to ER stress (73). 
These experiments also result in significant cell death. Specifically, 
glucolipotoxicity refers to the glucose- and free fatty acid (FFA)- induced 
apoptosis. High levels of saturated fatty acids were also reported to increase 
apoptosis in rat and human islets (74). Glucose seems to be an important 
amplifier of lipotoxicity, but the mechanisms by which fatty acids and glucose 
induce ER stress and apoptosis are not entirely understood.  
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Experimental HFDs are given to mice to mimic the “Western” diet that 
will induce obesity and the complications that are associated with it, specifically 
insulin resistance and T2D. Currently, several mouse models for ER stress-
related genes have been developed, and administration of the HFD has led to a 
diabetic phenotype in many cases. For example, mice that are heterozygous for 
Xbp1, Eif2α, Sec61, and Pdx1 (a transcription factor that is responsible for 
endocrine differentiation and insulin gene expression) exhibit impaired glucose 
homeostasis in addition to other characteristics of diabetes while on the diet, and 
these characteristics were shown to be ER stress-dependent (47, 62, 75, 76). 
  
 Taken together, an extensive body of previous work demonstrates a 
critical role for UPR signaling in obesity and diabetes by mechanisms that are not 
fully elucidated. One outcome of the UPR that has garnered increasing attention 
is the ER-associated degradation (ERAD) pathway. Several of the UPR targets are 
genes encoding proteins that facilitate ERAD, which in principle provides the 
most rapid and direct means to clear the ER of potentially toxic proteins. In 
addition to its stress-induced role in the UPR, the ERAD pathway is also used to 
regulate the levels of specific enzymes, lipid carriers, and secreted proteins (77). 
For these reasons, ERAD plays an essential role in maintaining normal cellular 
physiology and preventing disease. 
  
1.4  ERAD and Protein Quality Control 
ERAD works in coordination with the quality control process to eliminate 
aberrant proteins and prevent intracellular toxicity of misfolded proteins (77). 
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The key steps of ERAD are substrate recognition and protein targeting to 
translocation machinery, retrotranslocation, ubiquitylation, and proteasomal 
targeting and degradation (78). Each step is highly complex and involves several 
components that operate in parallel during ER stress. The current understanding 
of ERAD is primarily based on genetic and biochemical analyses in yeast, a 
model organism that demonstrates the conservation and evolutionary 
importance of this process. This section will discuss the mammalian homologues 
of the yeast ERAD-related genes, although evidence for their roles is 
inconclusive.  
 The folding machinery involved in quality control plays an important role 
in the recognition of substrates that ultimately go on to be degraded. Most 
nascent proteins that enter the ER lumen are co-translationally modified with an 
N-linked oligosaccharide, GlcNAc2-Man9-Glc3 (of which GlcNAc2 is N–
acetylglucosamine, Man is mannose, and Glc is glucose). Glucosidases in the ER 
remove two terminal glucose residues and the resulting monoglucosylated N-
acetylglucosamine binds to lectin-like factors, which contain sugar-binding 
domains (79). Calnexin and calreticulan constitute the lectin machinery of the ER 
and are responsible for promoting proper folding of glycoproteins. Following 
release from the calnexin-calreticulan folding cycle, the final glucose is removed 
and the resulting glycoprotein contains a GlcNAc2-Man9 moiety. The addition of 
an oligosaccharide unit to a protein contributes to backbone stability, and 
attaining the native conformation prevents exposure of hydrophobic patches. If 
exposed, as in an unfolded state, these patches can lead to aggregation (80). In 
this case, the misfolded protein is recognized by UDP-glucose:glycoprotein 
glucosyltransferase (UGGT), which adds a glucose to the glycan (81). This 
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prompts its re-entry into the calnexin-calreticulan cycle until the protein’s final 
conformation is achieved.  
Similarly, disulfide bond formation promotes protein stability and 
facilitates assembly into multimeric complexes. Protein disulfide isomerases 
(PDIs) catalyze the formation of disulfide linkages while also maintaining an 
oxidizing environment within the ER (82). In addition to the calnexin-calreticulan 
cycle and PDI, the 70 kDa heat shock protein- family of chaperones play a major 
role in proper protein folding (83). This family of chaperones includes GRP78 (or 
BiP), which has an established role in initiating the UPR. Its molecular structure 
enables GRP78 to bind client misfolded proteins with high affinity to prevent 
aggregation (84). Together, GRP78, lectin-like factors, and disulfide isomerases 
work in coordination with other distinct families of proteins to identify 
terminally misfolded proteins (both glycosylated and non-glycosylated) and 
target them to the retrotranslocon at the ER membrane (85, 86). 
 The targeting step of ERAD is closely associated with substrate 
recognition. The factors involved at this step are typically lectin-like proteins 
with domains capable of binding mannose-containing derivatives. For example, 
EDEM contains a α-mannosidase-like domain, while OS9 and XTP3-B contain a 
mannose-6-phosphate receptor-like domain(87-89). It is believed that these three 
proteins function in delivering substrates to the retrotranslocation channel.  
 The retrotranslocation step extrudes the misfolded proteins from the ER 
lumen and ultimately deposits them into the cytoplasm. Candidates for this 
channel include the SEC61 complex and the derlin family of proteins (DER1, 
DER2, DER3) (90, 91) . As an intermediate step, the retrotranslocation machinery 
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interacts with both targeting and ubiquitylation machinery. Ubiquitylation is the 
process of targeting a misfolded protein for proteasomal degradation and 
requires an E1 ubiquitin-activating enzyme (e.g. UBE1), an E2 ubiquitin-
conjugating enzyme (e.g. UBC6e), and an E3 ubiquitin ligase (e.g. HRD1-SEL1L 
complex) (92-94) . The AAA+ ATPase, p97, provides energy for further extracting 
the ubiquitylated protein into the cytoplasm. While the retrotranslocation and 
ubiquitylation components are ER membrane-localized, p97 is associated with 
the membrane via its interaction with VIMP (91, 95). It can also associate with the 
19S cap of the 26S proteasome, which provides a convenient segue for direct 
degradation of substrates.  Ubiquitin receptors (RPN10, RPN13, RPN5) in the cap 
facilitate the initial interaction with the substrate, which is ultimately moved into 
the 20S catalytic core for fragmentation into smaller peptide units (96, 97).  
 Impairment of ERAD has been shown to contribute to several diseases. 
Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, cystic fibrosis, 
and pulmonary emphysema are all associated with an accumulation of 
misfolded proteins and defective ERAD (98-101). These findings reinforce the 
potential importance of ERAD in maintaining ER and cellular homeostasis. 
However, it must also be acknowledged that ERAD works in coordination with 
another protein quality control process, known as autophagy(102). Autophagy is 
the engulfment of misfolded proteins or protein aggregates within double-
membrane vesicles that subsequently fuse to a lysosome, containing the proper 
enzymes for degrading the contents (103). Further experimentation is needed to 
determine the circumstances under which autophagy or ERAD dominate in 
removing misfolded proteins. In addition to these traditional degradation 
pathways, a novel mechanism of protein translocation has also been discovered. 
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In the condition of acute ER stress, certain secreted and membrane proteins are 
directly rerouted into the cytosol for proteasome-mediated degradation (104). 
This process, termed preemptive quality control, is signal sequence-dependent 
and reduces the burden of misfolded proteins entering the ER lumen.  
Given the causal connection between protein misfolding and human 
disease, it is important to understand the role of ERAD in mammalian 
physiology. Although evidence points to the activation of the UPR in target 
tissues affected by obesity and diabetes, the importance of the ERAD mechanism 
in the pathophysiology of metabolic disease has not been extensively 
investigated. SEL1L is an ER membrane protein with a complex structure that 
enables it to confer many versatile functions. The cellular functions of SEL1L 
have been explored in a wide range of species, from C. elegans to A. thaliana to 
human cell lines. 
 
1.5  SEL1L Protein Structure  
SEL1L, or Suppressor-Enhancer-Lin-12-1-Like, is the mammalian ortholog of 
the Sel-1 gene in C. elegans. It was originally identified in a genetic screen as a 
negative regulator of Notch (Lin-12) signaling, a pathway that specifies cell fate 
and directs differentiation (105). The human SEL1L gene is located on 
chromosome 14q24.3-q31 and consists of 21 exons, ultimately encoding a 794-
amino acid full-length protein. This region of chromosome 14 includes only five 
other protein-coding genes, and SEL1L is at the boundary of a so-called  “gene 
desert area” (106). The evolutionary origin and functional significance of these 
large areas devoid of genes is mostly unknown. Some evidence suggests that 
gene deserts resist chromosomal rearrangements and contain multiple distant 
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regulatory elements physically linked to their flanking genes, allowing the 
integrity of SEL1L’s structure and function to be maintained (107). The 
evolutionary importance of SEL1L is demonstrated in its high cross-species 
conservation. Its primary sequence is conserved in bacteria and yeast, but 
advanced structural complexity of gene during evolution suggests a divergence 
in its function (108).  
At the protein level, the human SEL1L shares 99% amino acid identity 
with chimpanzee, 97% with dog, and 93% with mouse.  Although similarity to A. 
thaliana and S. cerevisiae is lower, the protein structure still shares strict amino 
acid identity at the C-terminal region in these species. The protein structure of 
SEL1L contains several unique domains that most likely contribute to its 
potentially diverse functions in vivo (demonstrated in Figure 1.4).  
 
Figure 1.4: SEL1L Protein Structure. The SEL1L protein in multimodular, 
with protein-protein interactions reinforced by the fibronectin type II domain 
(FNII), the Sel1-like repeats, and the proline tail. The Sel1-like repeat clusters and 
the Hrd3 motif are conserved in lower organisms.  
 
  
The N-terminal end of SEL1L contains a fibronectin type II domain (FNII). Aside 
from fibronectin, this collagen-binding domain is also found in a range of 
proteins, including blood coagulation factor XII, bovine seminal plasma proteins, 
and mannose-6-phosphate receptor (109, 110). This domain also enables binding 
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to heparin, DNA and actin. It is not conserved in SEL1L invertebrate orthologs 
and only appears in the chordate lineage, indicating that this domain likely 
confers a new function for the full-length protein in higher organisms (106). 
Another distinct feature of the SEL1L structure is a set of three tandem clusters of 
SEL-1-like repeats. These repeats are a subtype of tetratricopeptide repeats (TPR), 
which contain two antiparallel alpha-helices. TPR motifs in a series generate a 
right-handed helical structure with an amphipathic channel that might 
accommodate the complementary region of a target protein (111). These units 
can mediate protein-protein interactions and have proven to play essential roles 
in protein folding, protein transport and cell cycle regulation. The Sel1-like 
repeats are highly conserved in SEL1L’s taxonomic evolution. Adjacent to the 
last repeat cluster, towards the C-terminal end of the protein, is the Hrd3-like 
motif. This motif was originally found in the yeast Hrd3p protein, which acts at 
the ER membrane as an E3 ubiquitin ligase (as described previously). It is the 
most highly conserved motif in the SEL1L protein sequence. At the C-terminal 
end is a proline-rich motif, which also serves the function of making protein-
protein interactions more favorable. This motif can facilitate intermolecular 
interactions such as signal transduction, cell-to-cell communication, and 
cytoskeletal organization (112). Other notable sequences in the SEL1L protein 
include a cleavable signal peptide, a PEST sequence (target for rapid 
degradation), an ER membrane-localization signal, and a transmembrane 
domain.  
Existing experimental evidence points to at least five SEL1L isoforms, 
likely resulting from alternative splicing events in the full-length mRNA. 
SEL1LA corresponds to the full-length protein structure depicted in Figure 1.4, 
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which localizes at the ER. Two variants of SEL1LA have recently been identified 
and designated p38 and p28. Studies in breast cancer carcinoma cell lines 
indicate that these N-terminal derivatives are also responsive to ER stress, but 
localize at endosomal vesicles (113). Isoforms SEL1LB and –C retain most of the 
N-terminal region of the protein, including the FNII domain and part of the SEL-
1-like repeats. Studies in human cell lines demonstrate that both of these 
isoforms are secreted glycoproteins, also found in secretory and degradative 
compartments and areas of cell-to-cell contact (114). SEL1LD includes only the 
evolutionarily conserved Hrd3 motif and the transmembrane domain, while –E 
is a further truncated version of SEL1LB/C (106).  
 
1.6  SEL1L Expression and Function 
SEL1L immunohistochemical staining in both human fetal and adult 
tissues illustrates the ubiquitous expression of SEL1L throughout the whole 
organism (115). However, staining appears to be most intense in protein-
secreting cells of mostly endocrine tissues. These tissues include the breast, 
prostate, salivary gland, thyroid, and pancreas (both acinar and endocrine cells). 
Analysis of SEL1L expression in fetal tissues also shows strong neuroepithelial 
staining at an early stage of human development (6-7 weeks). At later stages of 
development, SEL1L expression transitions to protein-secreting structures such 
as the liver and pancreas (106). 
 As a constituent of ERAD, this role of SEL1L has been extensively studied 
in lower organisms and mouse and human cell lines. For example, in C. elegans, 
RNAi-mediated knockdown of sel-1 results in the upregulation of GRP78 in an 
xbp1-dependent manner (116). Conversely, pancreatic islets from Akita mice, 
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with constitutive expression of misfolded insulin, show an upregulation of both 
HRD1 and SEL1L in comparison to wild-type mice (117). Molecular and 
biochemical analyses in mammalian cell lines have led to the development of an 
advanced ERAD model, operating at the interface of the ER and cytosol (91, 118). 
SEL1L most likely participates in the retrotranslocation of misfolded proteins by 
associating with HRD1 and facilitating the movement and ubiquitylation of 
ERAD substrates. This function is represented in Figure 1.5: 
 
 
Figure 1.5: The Role of SEL1L in the Retrotranslocation of Misfolded Proteins: 
Molecular and biochemical analyses implicate a role for SEL1L at the 
translocation step of ER-associated degradation (ERAD). It nucleates the complex 
responsible moving misfolded proteins from the ER lumen and into the cytosol. 
It is associates with the E3 ubiquitin ligase, HRD1, the derlin family of proteins, 
and OS9. 
 
  
 Although evidence mostly suggests that ERAD is the primary function of 
SEL1L, other studies have highlighted its potential role in proliferation and 
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consequently in cancer. This function could be modulated by its interaction with 
Notch or by involvement in the TGF" pathway (119).  
 
1.7  SEL1L and Disease 
A significant downmodulation of SEL1L expression was seen in breast 
cancer and pancreatic cancer, both in vivo and in vitro, suggesting that it may 
have tumor suppressor activity (120, 121). Histopathalogical analysis also 
revealed that SEL1L is a predictive marker for cell transformation, from adenoma 
to carcinoma, in cancers of the esophagus, breast, pancreas, prostate, lung and 
colon (122-126). An increase in its expression at this stage may be a mechanism 
by which cancerous cells enhance their survival and ability to cope with protein 
synthesis. With regard to neurological disorders, a polymorphism in SEL1L 
intron 3 is linked to susceptibility to Alzheimer’s Disease in Italian patients, 
while a homozygous mutation in a highly conserved Sel1-like repeat is 
associated with early-onset cerebellar ataxia in Finnish hounds (127, 128). The 
latter association is also correlated to an elevation of ER stress markers in the 
cerebellum of affected dogs.  
The SEL1L gene can also be indirectly associated with liver and pancreatic 
diseases due to its promoter activity. Two transcriptional regulators, hepatocyte 
nuclear factor-1! and -4! (HNF), are considered master regulators of hepatocyte 
and islet transcription and specifically bind the SEL1L promoter in these cell 
types. Mutations in these factors are seen in patients with mature-onset diabetes 
of the young (MODY), a monogenic and rare form of diabetes (129). 
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1.8  Research Goal  
In summary, the molecular mechanisms of T2D are incompletely 
understood. Increasing evidence suggests that ER stress plays an important 
causative role in the development of insulin resistance and β-cell dysfunction, 
two essential characteristics of T2D. A better understanding of the UPR and 
ERAD pathways, key cellular adaptive mechanisms to ER stress, would likely 
lead to new strategies for the treatment of T2D and other diseases associated 
with misfolded proteins. Interestingly, SEL1L is highly expressed in tissues 
involved in the pathogenesis of T2D, namely the liver, pancreas, and brain. 
However, the in vivo function of SEL1L remains unknown. Therefore, the 
overarching aim of this dissertation is to determine the physiological role of 
SEL1L in the whole organism , with emphasis on glucose and energy balance. In 
order to address this, our lab has developed two mouse models. The first is a 
Sel1L global knockout generated by a targeted gene trap insertion (Figure 1.6). 
The second exhibits Cre-mediated recombination of a floxed (Flanking lox P sites) 
Sel1L allele (Figure 1.7). The characterization of these models has provided 
invaluable insight into the genetic basis of T2D and a possible cause of cellular 
dysfunction in this disease state.  
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Figure 1.6: The Global Sel1L Knockout Mouse Model. The 
first mouse model for Sel1L was generated through the insertion of 
a gene trap in intron 14. The gene trap consists of a splicing 
acceptor (SA) attached to β-galactosidase and neomycin cassette (β-
Geo). The mutant mice express a truncated version of the SEL1L 
protein conjugated to β-galactosidase, due to abnormal splicing. 
 
 
 
  
  
Figure 1.7: The Conditional Sel1L Knockout Mouse Model. These mice 
contain a targeting vector with lox P recombination sites flanking exon 6 of the 
Sel1L gene. The vector also contains a β-galactosidase and neomycin cassette (β-
Geo) for selection, flanked with frt recombination sites. Once the target vector is 
integrated into the genomic DNA, the selection cassette is removed by crossing 
with mice overexpressing the Flp transgene. After, crossing with mice over-
expressing the Cre transgene in particular tissues will disrupt Sel1L gene 
expression. 
 
The second chapter will focus on the biological importance of Sel1L and its 
function in degradation of misfolded proteins during development. Next, I will 
elucidate a critical role for SEL1L in insulin secretion. In the fourth chapter, I will 
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explore the role of ERAD in the neuronal pathways that regulate food intake and 
body weight. Finally, I will propose a model for the role of ER stress in the 
pathogenesis of T2D and targets for a clinical approach to treat this potentially 
fatal and costly disease.    
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CHAPTER 2: THE ROLE OF Sel1L IN MOUSE EMBRYONIC 
DEVELOPMENT  
2.1  Abstract 
 The mouse and human Suppressor-Enhancer-Lin-12-1-Like (Sel1L) gene 
encodes a structurally complex protein with exceptionally high expression in the 
adult pancreas and central nervous system. Evidence from in vitro studies in 
lower organisms implicates a role for SEL1L in ERAD, a proteosome-mediated 
pathway induced by the accumulation of terminally unfolded or misfolded 
proteins in the endoplasmic reticulum (a condition referred to as ER stress).  
However, its physiological role in the whole organism remains elusive. The Long 
lab has generated mice carrying a gene trap insertion in intron 14 of the Sel1L 
gene. Mice homozygous for the mutation (Sel1L-/-, mutant) die during mid-
gestation, with increased apoptosis in the liver and central nervous system. 
Furthermore, electron microscopy revealed distention and fragmentation of the 
ER and altered ultrastructural morphology in the Sel1L-/- embryonic liver. Mouse 
embryonic fibroblasts (MEFs) derived from embryonic day 12.5 were used to 
further characterize the cellular phenotypes of the Sel1L mutants. The 
proliferation of Sel1L-/- MEFs was significantly reduced as compared to the 
Sel1L+/+ (wild-type) and Sel1L+/- (heterozygous) MEF counterparts. 
Pharmacological challenge of the MEFs with tunicamycin, an N-glycosylation 
inhibitor, revealed that Sel1L-/- MEFs are sensitive to ER stress, and exhibit 
decreased cell viability in comparison to Sel1l+/+ MEFs. Finally, immunoblot and 
immunocytochemical analyses indicated Sel1L-/- MEFs have a compromised 
ability to degrade misfolded proteins. Together, these results suggest that Sel1L is 
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critically required for maintaining ER homeostasis during mouse embryonic 
development. 
 
2.2  Introduction 
 The endoplasmic reticulum (ER) maintains an ideal environment for 
protein folding, maturation and transport. This is achieved by the collective 
function of chaperones, glycosylation enzymes, and reductases within the ER 
lumen. Additionally, a sophisticated quality control system exists in the ER to 
retrieve improperly folded proteins (130). This system ensures that misfolded 
proteins are retained in the ER for further folding cycles, or targeted for 
proteasome-mediated degradation in the cytosol. Despite these optimal 
conditions for protein folding, the load of protein entering the ER lumen can 
exceed its folding capacity. Alterations in ER homeostasis lead to an 
accumulation of misfolded or unfolded proteins, a condition termed “ER stress.”  
There are many physiological and environmental causes of ER stress, 
including oxidative stress, glucose deprivation, viral infection, and genetic 
mutations (131). To cope with this intracellular disturbance, eukaryotic cells 
employ a highly conserved pathway, known as the unfolded protein response 
(UPR), to restore homeostasis. The UPR is mediated by three ER membrane-
associated proteins, PERK, IRE1!, and ATF6!, which ultimately affect changes in 
gene expression in response to ER stress (132). PERK phosphorylates eIF2! to 
attenuate protein translation and decrease the load of protein entering ER. 
Phosphorylated eIF2! also selectively stimulates ATF4 translation to induce 
transcriptional regulation of UPR genes. IRE1! cleaves XBP1 mRNA to a spliced 
form that acts as a transcription factor to upregulate UPR genes encoding factors 
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involved in ER protein folding and degradation. ATF6! traffics to Golgi for 
cleavage by S1P and S2P to release a nuclear form of ATF6! that works 
synergistically or separately with XBP1s to regulate UPR gene expression (26). 
UPR signaling pathways therefore converge to give rise to several general 
outcomes to attenuate ER stress. They include an increase in the transcription of 
chaperones, a decrease in overall translation, and enhanced ERAD. ERAD is part 
of the cell’s normal quality control surveillance system, but essentially works in 
coordination with other UPR processes to maintain ER homeostasis. In fact, 
induction of the UPR increases ERAD capacity, and ERAD efficiency requires an 
intact UPR (133). During ERAD, chaperones in the ER recognize terminally 
misfolded proteins and target them to machinery at the interface of the ER and 
cytosol, known as the translocon. The translocon then ubiquitylates the substrate 
and provides energy for its extrusion into the cytosol, where it is a target for 
proteasome-mediated degradation (78).  
Misfolded proteins are associated with a host of diseases, including 
pulmonary emphysema, cystic fibrosis, Alzheimer’s Disease, and diabetes (134). 
This affirms the essential role of both the UPR and ERAD in normal physiology. 
ERAD factors have been identified through genetic and biochemical approaches, 
many conserved from yeast to humans. Of particular interest is the Suppressor-
Enhancer-Lin-12-1-Like (SEL1L) protein, an ER transmembrane protein that 
nucleates the ERAD translocation machinery and interacts with components 
such as HRD1 (E3 ubiquitin ligase) and OS9 (substrate delivery to the translocon) 
(91, 118) .  Evidence from yeast, Arabidopsis thaliana, and human embryonic 
kidney 293 cells indicate that there is increased expression of the Sel1L transcript 
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during ER stress conditions (93, 135, 136). Furthermore, this upregulation is 
downstream of IRE1 and ATF6 activation.    
In humans, SEL1L appears to be highly expressed in the pancreas and 
central nervous system (106). Its multimodular protein structure enables it to 
have numerous potential functions, particularly those requiring protein-protein 
interactions. Yet the physiological role of SEL1L is mostly unknown. To 
determine this, the Long lab at Cornell University has developed the first 
knockout model for Sel1L (137). This model uses a gene trap insertion, consisting 
of a splice acceptor fused to a β-galactosidase-neomycin (β-geo) cassette, between 
exons 14 and 15 of the Sel1L gene. Therefore, the disrupted transcription results 
in a truncated SEL1L protein fused with β-geo in the mutant mouse (Sel1L-/-). 
Heterozygous mice (SelL+/-) show no observable phenotypic difference in 
comparison to wild-type mice (Sel1L+/+), and were used in mating to generate 
mutant mice. From these matings, no live Sel1L-/- mice were produced, 
suggesting the homozygous mutation is embryonically lethal in mice. Based on 
genotyping and morphological characterization at various embryonic stages, it 
was determined that nearly half of the Sel1L-/- mice are not alive by embryonic 
day 11.5 (E11.5) (137) . Thus, SEL1L is essential for mouse embryonic 
development. 
Based on the previous evidence regarding SEL1L function, we speculate 
that the loss of SEL1L will disengage cellular ERAD, and therefore an entire arm 
of the UPR process. In order to understand the in vivo function of SEl1L during 
development, the embryological phenotype of the Sel1L-/- mice was characterized 
using cellular, biochemical, and molecular techniques.  
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2.3  Materials and Methods 
Mice 
The Sel1L global knockout mice were generated by a gene trap insertion (SA-β-
geo-polyA) between exons 14 and 15 of chromosome 12. The gene-trapped 
mouse embryonic stem cell line, CA0017 (Sanger Institute Gene Trap Resource), 
was microinjected into C57BL/6 blastocysts. The resulting chimeric male 
founders were backcrossed to C57BL/6 females to generate heterozygous mice. 
Sel1L+/− mice were then intercrossed to generate homozygous Sel1L-/- embryos. 
The following primers were used for genotyping the embryos and mice: F1-Sel1L, 
5%-TGGGACAGAGCGGGCTTGGAAT-3%; R1-Sel1L, 5%-
CACCAGGAGTCAAAGGCATCACTG-3%; R-βGeo, 5%-
ATTCAGGCTGCGCAACTGTTGGG-3%. All animal experiments were performed 
in accordance with the Cornell Animal Care and Use Guidelines. 
 
TUNEL Assay 
 Embryos were dissected from pregnant females at E12.5 and fixed 
overnight in 4% PFA/PBS. The next day, they were washed several times with 
phosphate-buffered saline (PBS) and stored overnight in a 30% sucrose/PBS 
solution. The following day, they were embedded in OCT and frozen on dry ice 
before subsequent storage at -80°C. Staining was performed according to 
instructions for the Chemicon International Apoptog Peroxidase In Situ 
Apoptosis Detection Kit S7100 (Millipore Corporation). The ImmPact DAB 
peroxidase kit (Vector Technologies) was used as the substrate, and a 
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hemotoxylin counterstain (Gill’s, diluted 1:10) was applied. Results were 
visualized using light microscopy.  
 
Transmission Electron Microscopy 
 Embryos were dissected from a pregnant female at E12.5. Using a 
dissection microscope, the livers from each embryo were removed and fixed in 
Karnovsky’s Fixative Mix (EMS technologies: 2% PFA, 2.5% Glutaraldehyde, 0.1 
M Na-phosphate buffer) at 4° for 3 hours, then washed with the Na-phosphate 
buffer, 3 X 10 minutes. Post-fixation in 1% osmium tetraoxide, sectioning, and 
additional post-fixation in uranyl acetate were done by the Electron Microscopy 
and Histology Core Facility, Department of Cell and Molecular Biology, Weill 
Cornell Medical College for. Image capturing was performed using the JOEL 
100CX-II transmission electron microscope. 
 
Mouse Embryonic Fibroblast (MEF) Cell Lines 
 To establish MEF cell lines from each genotype, embryos were dissected at 
E12.5–E13.5 of gestation and homogenized in 1 ml of MEF media (Dulbecco's 
modified Eagle's medium with 10% fetal bovine serum, 1% sodium pyruvate, 1% 
Glutamax, and 1% Pen-Strep). The homogenate was plated in a 6-cm dish with 5 
ml of media and cultured overnight. The next day, cells were passaged 1:1 to 
remove any large, dead debris. Cells were then split 1:3 every 2–3 days. To 
establish immortalized MEF cell lines, primary MEF cells of defined genotypes 
were maintained at 80–90% confluency in 10-cm dishes for two to three months. 
To generate the growth curve, MEFs were plated at a density of 2 X 104 cell/well 
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in a 6-well plate and collected for counting using a hemocytometer 2, 4, and 6 
days after plating. 
 
Crystal Violet Assay 
 Cell viability using the crystal violet assay was performed essentially as 
described (138). Briefly, MEFs from Sel1L+/+ and Sel1L-/- embryos were plated at a 
density of 2 X 105 cells per genotype in a 6-cm plate. The next day, they were 
treated with 2 &g/ml tunicamycin (TM) for 0, 1, 2, or 4 hours. After treatment, 
MEFs were trypsinized and re-plated into 10-cm plates and grown for 5 days in 
normal MEF media. Then, the media was removed and 1 ml of crystal violet 
(0.2% w/v in 2% ethanol) was added to each plate. Stained MEFs were 
solubilized with 600 &l of 1% SDS, and absorbance of the resulting solution was 
measured at 570 nm. Relative cell viability was calculated as a percentage of 
absorbance of TM-treated cells relative to that of non-TM treated cells. 
 
Expression Plasmids, MEF Cell Transfection, and Cycloheximide-Chase Assay  
The pNHK-GFP fusion expression plasmid was a kindly provided by Dr. 
Nobuko Hosokawa of Kyoto University. The full-length (FL) and dominant-
negative SEL1L-GFP fusion constructs were generated by PCR amplification of 
the corresponding Sel1L cDNA fragments followed by subcloning into the EcoRI 
and BamHI sites in pEGFP-N2 vector (Clontech). The PCR primers used to 
amplify the full-length and 5% portion Sel1L cDNA fragments were: F2-Sel1l, 5%-
GAATTCCGCCACCATGCAGGTCCGCGTCAGG-3%; R2-Sel1l, 5%-
GGATCCtCTGTGGTGGCTGCTGCTC-3%; R3-Sel1l, 5%-
GGATCCTAACTTGAACGCCTCTTCC-3%. The expression of fusion proteins was 
  39 
verified by GFP fluorescence microscopy in transfected HEK293 cells. MEFs of 
defined genotypes were seeded at a density of 500,000 cells/well in 6-well 
dishes. The next day, MEF cells were rinsed twice with PBS, once with Opti-
MEM reduced serum medium (Invitrogen), and incubated with 1 ml of Opti-
MEM reduced serum medium containing 3 &g of expression plasmid encoding 
GFP-tagged NHK (for co-transfection, 3 &g of each expression plasmid was used) 
and 2 &l of polyethylenimine. After incubation for 12-16 hours, the transfection 
media was removed, and cells were treated with 50 &g/ml of cycloheximide in 
normal media for 0, 1.5, 3, 4.5 or 6 hours. MEF cell lysates were prepared by 
adding 100 &l of RIPA buffer to each well, then using a cell scraper for collection. 
BCA was used for protein quantification of each lysate. For western blotting, 20 
&g of each lysate was mixed with an equal volume of 2X sample buffer (100 mm 
Tris, 25% glycerol, 2% SDS, 0.01% bromphenol blue, 10% 2-mercaptoethanol), 
boiled for 5 min and loaded into a 9% SDS-PAGE gel. Electrophoresis, blotting, 
and antibody probing were performed using standard procedures (139). 
Immunodetection was done using the Pierce ECL Western Blotting Substrate 
according to the manufacturer's specifications. GFP (Abcam) and tubulin (Cell 
Signaling) antibodies were used at 1:5,000 and 1:10,000, respectively). 
 
2.4  Results 
 
2.4.1  Sel1L-/- embryos show upregulation of UPR markers and increased 
apoptosis in the central nervous system 
TUNEL staining, as an indicator of apoptosis, was performed using frozen 
sections of Sel1L-/- and SelL1+/+ embryos isolated at embryonic day 12.5 (E12.5). At 
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this stage of mouse development, the expression of SEL1L is particularly high in 
the neural tube and dorsal root ganglia (106). As shown in Figure 2.1, 
significantly more TUNEL-positive cells (indicated the black arrows) were 
detected in the forebrain and dorsal root ganglia of the Sel1L-/- embryo than in the 
Sel1L+/+ embryo.  
 
Figure 2.1: Sel1L-/- embryos show increased apoptosis in comparison to Sel1L+/+ 
embryos. TUNEL assay for apoptosis in the forebrain (a,b) and dorsal root 
ganglia (c,d) of Sel1L+/+  (a, c) and Sel1L-/- (b, d) E12.5 embryos (10X magnification). 
Seen in Figure 3 of (137). 
 
 
Quantitative RT-PCR with Sel1L embryos also revealed an upregulation of 
several UPR markers in the Sel1L-/- embryo (137). These results indicate that the 
absence of Sel1L ultimately leads to apoptosis in localized regions of the brain. 
We speculated that the probable cause of this apoptosis in the mutant embryo is 
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the ER stress generated by the accumulation of misfolded proteins that are 
unable to be degraded due to lack of Sel1L.  
 
2.4.2  The endoplasmic reticulum in the Sel1L-/- embryonic liver shows a distorted 
morphology 
The liver is the largest internal organ in the mouse embryo, and has 
essential metabolic, endocrine, and exocrine functions. As a productive organ in 
terms of relative protein synthesis and secretion, it is highly susceptible to ER 
stress and the UPR. During mouse development, the mouse liver bud undergoes 
accelerated growth between E9.5 and E15 (140).  
To determine if SEL1L-deficiency causes morphological changes in the ER 
of mouse embryonic cells, the liver bud was isolated from E12.5 Sel1L-/- and 
Sel1L+/+ embryos for electron microscopic observation. The images, shown as 
Figure 2.2, revealed the mutant liver ultrastructure is distorted in comparison to 
the wild-type liver ultrastructure.  
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Figure 2.2: The endoplasmic reticulum in the Sel1L-/- embryonic liver shows a 
distorted morphological ultrastructure. Electron microscopy of Sel1L embryonic 
liver buds with, (a) Sel1L+/+ embryonic liver, 19000X (b) Sel1L-/- embryonic liver, 
19000X (c) Sel1L+/+ embryonic liver, 29000X (d) Sel1L-/- embryonic liver, 29000X. 
Seen in Figure 2 of (137). N= Nucleus, ER= Endoplasmic reticulum, M= 
Mitochondria 
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The Sel1L-/- hepatocytes (2.2b and 2.2d) exhibited distention of the endoplasmic 
reticulum membranes and had mitochondria that are deformed and appeared 
less abundant than in the Sel1L+/+ hepatocytes (2.2a and 2.2c). Alterations of ER 
morphology are another indication of the presence of ER stress. The changes in 
mitochondrial numbers and morphology further suggest that sustained ER stress 
may cause pivotal changes in the mitochondrial structure that go on to mediate 
proapoptotic signaling (141).  
 
2.4.3  Sel1L-/- MEFs exhibit growth retardation and decreased cell viability 
 Mouse embryonic fibroblasts (MEFs), derived from E12.5 Sel1L embryos, 
allow the extrapolation of the function of Sel1L in growth and development in an 
in vitro model. The growth curve for the primary Sel1L MEFs (Figure 2.3) 
indicated that within two days of plating, the Sel1L-/- MEFs show significantly 
slower growth than both the Sel1L+/+ and Sel1L+/- MEFs. The Sel1L+/- MEF growth 
phenotype is similar to that of the Sel1L+/+ MEF phenotype, and a minor 
difference was observed between the two genotypes over the six-day growth 
period. The cause of growth retardation in Sel1L-/- MEFs is currently unknown 
but could be attributed to the activation of the translational attenuation pathway 
of the UPR. Although the interplay between ERAD and other pathways is poorly 
defined, endogenous ER stress due to a defective ERAD pathway can 
compromise the growth of the cell as protein aggregation increases.  
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Figure 2.3: Sel1L-/- MEFs show growth retardation in comparison to their 
Sel1L+/+ MEF counterparts. These are growth curves of Sel1L primary MEFs 
(E12.5) for each genotype. MEFs were isolated and seeded at a density of 2 X 104 
cells per well in a 6-well plate (Day 0). *, p<0.01, mutant versus wild-type (n=3 
independent experiments). 
 
Immortalized MEFs were developed from the primary cell culture and 
used to analyze the MEF response to exogenous stress. Sel1L-/- MEFs and Sel1L+/+ 
MEFs were treated with tunicamycin (TM, 2 µg/ml) for up to 4 hours (Figure 
2.4a). Tunicamycin induces ER stress by blocking N-linked glycosylation of 
newly synthesized glycoproteins, thus causing an accumulation of improperly 
folded proteins within the lumen of the endoplasmic reticulum (138). The Sel1L-/- 
MEFs displayed a sharp decrease in cell viability over time in comparison to the 
Sel1L+/+ MEFs, as quantified by a crystal violet assay. Thus, Sel1L-/- MEFs are more 
susceptible to exogenous ER stress than Sel1L+/+ MEFs. Although the 0 hour time 
point for the mutant MEFs was originally less viable than its wild-type 
counterpart, the percent viability seen in Figure 2.4b was calculated as a ratio of 
the absorbance of the ER-stressed samples (1, 2, 4 hour) to the non-ER-stressed 
samples (0 hour).  
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b 
 
Figure 2.4: Sel1L-/- MEFs have decreased cell viability in response to TM. 
Shown is the response of Sel1L MEFs to tunicamycin (TM), with hours of TM 
treatment (2 µg/ml). (a) An equal number of E12.5 MEFs (2 X 105) from each 
genotype were plated in 6 cm dishes and treated with TM for the indicated 
periods of time. After incubation with TM, cells were trypsinized and re-plated 
in 10 cm dishes and grown for 5 days. Then, cells in each plate were stained with 
the crystal violet stain for viable cell nuclei and (b) quantified after solubilization 
in 1% SDS and spectrophotometer reading (at 570 nm). Relative cell viability at 
each time point was calculated as a percentage of the non-TM-treated plates (0 
hour time point) for each genotype. *, p<0.01, **, p<0.001 (n= 3 independent 
experiments). Seen in Figure 3 of (137). 
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2.4.4  Sel1L-/- MEFs have an impaired ability to degrade misfolded proteins 
 Null Hong Kong (NHK) is an α1-antitrypsin variant. As a terminally 
misfolded protein, it has been well established in literature as a known substrate 
of ERAD (142). To assess if Sel1L-/- cells have a reduced ability to dispose 
misfolded proteins, we transfected Sel1L-/- MEFs with an NHK-GFP expression 
plasmid and performed cycloheximide-based protein chase (cycloheximide is a 
translational inhibitor in eukaryotic cells). Western blot analysis indicated that 
the Sel1L-/- MEFs show retention of the misfolded protein, while there was a 
normal physiological degradation of it in the Sel1L+/+ MEFs (Figure 2.5a). These 
results are recapitulated with Sel1L-/- MEFs which are co-transfected with either a 
plasmid expressing a truncated Sel1L (dominant-negative) or full-length Sel1L. 
Again, there was an impaired degradation of NHK when it is co-transfected with 
the truncated construct, but this phenotype is rescued by expression with the 
full-length construct. Live imaging of the NHK-GFP fluorescence also reinforced 
this pattern in the Sel1L-/- and Sel1L+/+ MEFs (Figure 2.5b). 
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b 
 
Figure 2.5: Sel1L-/- MEFs have an impaired ability to degrade misfolded 
proteins. (a) From left to right, transfection of NHK-GFP and GFP in wild- type 
MEFs, mutant MEFs, mutant MEFs co-transfected with a truncated Sel1L variant, 
and mutant MEFs co-transfected with full-length Sel1L. (b) Degradation of NHK-
GFP in Sel1L MEFs, seen with fluorescent microscopy, 40X magnification; NHK = 
Null Hong Kong Antitrypsin Variant; Chx = Cycloheximide (translational 
inhibitor) 
 
2.5  Discussion 
 Here, we report the first in vivo functional analysis of SEL1L. Using a 
gene-trapped mouse model that disrupts gene and protein expression, we find 
that a homozygous mutation in Sel1L causes early gestational lethality. This is 
the first evidence indicating that Sel1L is required for mammalian development. 
Furthermore, the embryonic deficiency of SEL1L was shown to increase the 
expression of UPR markers, induce apoptosis in the central nervous system, 
cause ER stress in the liver, and reduce cell growth and cell viability. The likely 
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cause of this systemic phenotype is an impaired degradation pathway in 
embryonic cells, preventing the extrusion of misfolded proteins from the ER 
lumen. Taken together, these results suggest that SEL1L is necessary for overall 
ER homeostasis during mouse embryonic development.  
 This gene trap insertion in Sel1L results in the deletion of the carboxyl-
terminal end of the SEL1L protein. This mutation eliminates several highly 
conserved motifs and domains in the protein structure, including the Hrd3p 
motif (also seen in the yeast ortholog) and the transmembrane domain (106). We 
predict that the gene trap in this model would disrupt SEL1L’s function in 
ERAD, as the protein can no longer localize to the membrane and facilitate 
degradation. However, we have not confirmed the deletion of all potential 
isoforms of SEL1L and recognize the possibility of alternative functions for the 
truncated Sel1L allele. Indeed, it has been reported that several other alternative 
transcripts are derived from alternative splicing of Sel1L mRNA (106). Thus, 
further studies are necessary to completely understand the functions of Sel1L. 
 SEL1L has been proposed to operate at the translocation step of ERAD. It 
interacts with several other proteins to remove misfolded proteins from the ER 
lumen and target them for degradation in the cytosol under normal and ER 
stress conditions (91, 118). In vivo and in vitro evidence from our mouse model 
supports this function. First, we show that the absence of Sel1L induces the 
unfolded protein response and apoptotic pathways. Quantitative real-time PCR 
data collected by Anish Vani, showed that markers such as Bip, Hrd1, p58IPK, and 
Erdj3 are upregulated in whole Sel1L-/- embryos (137). These genes are established 
markers of ER stress because transcriptional regulators of the UPR induce their 
expression to alleviate the burden within the ER. Immunohistochemistry 
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detected increased apoptosis in regions of the central nervous system of the 
Sel1L-/- embryos (Figure 2.1). Neurons in the forebrain and dorsal root ganglia 
undergo massive growth and differentiation during vertebrate development, and 
rely on protein synthesis for synaptic formation (143). The presence of ER stress 
in the central nervous system of the Sel1L-/- embryo activates the UPR, yet the 
UPR is unable to successfully adapt and instead initiates apoptotic pathways. 
Secondly, we showed that in embryonic liver, Sel1L is required for maintaining 
hepatocyte organelle morphology and function. The liver is another organ with a 
relatively high biosynthetic load during development (and postnatally). Sel1L-/- 
embryonic livers display evident ER stress in electron micrographs, 
demonstrating that ERAD dysfunction leads to an accumulation of misfolded 
proteins (Figure 2.2). Thirdly, we show that in mouse embryonic fibroblasts 
(MEFs), Sel1L is required for growth and cell viability in conditions of exogenous 
ER stress (Figures 2.3 and 2.4). Finally, we have proven that Sel1L is required for 
proper degradation of unfolded proteins. Using a cycloheximide-chase 
experiment to detect levels of transfected NHK, a known ERAD substrate, we 
show that there is reduced degradation of the NHK protein in Sel1L-/- MEFs over 
time (Figure 2.5). In other functional data collected by Adam Francisco, mutant 
MEFs also exhibit impaired secretion as determined by a Guassia Luciferase 
reporter assay (137). Overall, the presence of ER stress caused by the lack of Sel1L 
affects cellular survival and function. Further studies would be necessary to 
determine the specific cause of embryological death in this mouse model.   
 Mouse models of other ERAD components have yielded similar 
phenotypes to what we have seen with the Sel1L global knockout. For example, 
complete loss of Hrd1 and Derlin1 result in embryonic lethality and systemic ER 
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stress as well (144, 145). Only the Derlin1-deficient mice, however, showed 
obvious growth retardation during development. Loss of other ERAD proteins, 
such as Derlin3 and Herp, show no effect on embryogenesis and growth in mice. 
Despite the lack of an overt ER stress-related phenotype, Herp-deficient mice 
display impaired glucose tolerance and susceptibility to brain ischemic injury. 
Collectively, these mouse models point to a close link between embryogenesis 
and the quality control of proteins and reinforce the notion that SEL1L functions 
through interacting with other ERAD components. 
 The current mouse model, while proven valuable for understanding the 
role of Sel1L in embryonic development, has limitations in dissecting SEL1L 
function in adult tissues. SEl1L has high expression in the pancreas and the 
central nervous system, most likely because of the high capacity for protein 
secretion in these areas. Therefore, SEl1L may be necessary for cell viability and 
function in the pancreas and brain. ER stress and insufficient secretion, caused by 
loss of Sel1L, could play a role in neurodegenerative disease or metabolic 
disorders.  
   To summarize, studies of the first mouse model has shown that Sel1L is 
critical for development. Embryological, in vitro, and in vivo data implicate the 
existence of endogenous ER stress and greater susceptibility to exogenous ER 
stress in Sel1L-/- mice. There is also severely defective degradation of misfolded 
proteins, and impaired secretion of proteins in Sel1L-deficient cells. Therefore, 
SEL1L is necessary for ER, cellular, and whole organism homeostasis. Future 
studies regarding the physiological role of SEL1L will likely be carried out using 
a conditional mouse model to dissect the tissue-specific functions of SEL1L. 
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CHAPTER 3: THE ROLE OF Sel1L IN PANCREATIC β-CELLS AND GLUCOSE 
HOMEOSTASIS 
3.1  Abstract 
Suppressor-enhancer-lin12-1-Like (Sel1L) encodes a factor present at high 
abundance in the mature pancreas. As a type I endoplasmic reticulum (ER) 
membrane protein, SEL1L has previously been implicated in ERAD, a protein 
quality control process that is crucial for maintaining ER homeostasis.  We have 
reported the first mouse genetic mutation for Sel1L, a hypomorphic allele 
generated through gene trapping. While homozygous mice (Sel1L-/-) are 
embryonically lethal, heterozygous mice (Sel1L+/-) are viable and show a normal 
glucose metabolic profile when fed with a normal diet. We hypothesize that 
heterozygosity of Sel1L may impair the ability of mature β-cells to functionally 
adapt to increased insulin demand under the condition of insulin resistance. We 
first tested this hypothesis in a diet-induced obesity model.  Male Sel1L+/- mice 
and their wild-type littermates (10-weeks of age) were fed with a high-fat diet 
(HFD) for 24 weeks.  Sel1L+/- mice showed progressively higher fasting blood 
glucose levels than their wild-type control mice after 8 weeks of HFD feeding.  
At the end of the HFD-feeding period, Sel1L+/- mice were glucose intolerant and 
had an impaired glucose-stimulated insulin secretion (GSIS) as compared to 
wild-type mice. Pancreatic morphometry indicated that Sel1L+/- mice had a 
markedly reduced β-cell mass.  No observable increase of β-cell apoptosis but a 
significant decrease in β-cell proliferation was detected in the pancreas of Sel1L+/- 
mice.  Pancreatic islets isolated from Sel1L+/- mice showed elevated expression of 
unfolded protein response (UPR) markers, indicative of the presence of ER stress. 
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In vitro experiments using cultured mouse and rat insulinoma cell lines, 
ectopically expressing a deletion mutant SEL1L, also confirmed these in vivo 
findings.  To further investigate the function of SEL1L in the β-cell, we generated 
conditional Sel1L-defecient mice (Sellox/lox) and crossed them with mice expressing 
Cre under the control of the rat insulin II gene promoter (RIP-Cre). Mice with 
RIP-Cre-mediated deletion of Sel1L (Sellox/lox; RIP-Cre) showed elevated blood 
glucose levels in comparison to control mice (Sellox/lox and Sellox/+; RIP-Cre) by 2 
weeks of age. Additionally, Sellox/lox; RIP-Cre mice displayed a metabolic 
phenotype similar to that seen with HFD-fed Sel1L+/- mice. Immunohistochemical 
analysis of pancreata in Sellox/lox; RIP-Cre mice showed no changes in β-cell mass, 
but instead a pronounced trafficking defect in the proinsulin secretory pathway. 
Taken together, our in vivo and in vitro data strongly suggest that SEL1L has a 
critical functional role in the mature pancreas, most likely through maintaining 
normal β-cell proliferation and/or function.   
 
3.2  Introduction 
 Type 2 diabetes (T2D) is an emerging global epidemic, becoming the 
major health concern of the 21st century. In the United States, over 25 million 
Americans are diagnosed with T2D and there are alarming increasing trends in 
the population and the cost of this disease (3). T2D is understood to be a 
heterogenous disorder characterized by reduced β-cell mass and reduced insulin 
secretion in the setting of insulin resistance (146). As such, obesity is a well-
defined risk factor of T2D. The underlying mechanisms of β-cell loss and 
dysfunction in obese individuals, leading to the manifestation of T2D, remain 
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unknown. Accumulating evidence indicates an intracellular stress, localized at 
the endoplasmic reticulum (ER), may play a causal role in the development of 
this disease.  
 The ER is a highly specialized cytoplasmic organelle in which various 
metabolic signals and pathways are integrated to regulate protein, glucose, 
cholesterol, lipid and metabolism (147). As a principal site of protein synthesis, 
and together with the Golgi apparatus, it facilitates the transport and release of 
correctly folded proteins. Ribosomes attached to the ER membrane translate de 
novo peptides into the luminal space. Here, chaperones, glycosylation enzymes, 
and reductases create an optimal environment for proteins to achieve their native 
conformation. Non-native proteins are retained in the ER lumen and subject to 
further folding cycles as directed by a stringent “quality control” system (130).  
This system ensures that misfolded proteins are retained in the ER for further 
folding cycles, or targeted for proteasome-mediated degradation in the 
cytoplasm. Various conditions can disturb ER functions, including inhibition of 
protein glycosylation, a state of hypoxia, changes in calcium balance, impairment 
of protein transport from the ER to the Golgi, and overexpression of improperly 
folded proteins. Alterations in ER homeostasis lead to an accumulation of 
misfolded or unfolded proteins, a condition termed “ER stress.” ER stress elicits 
the unfolded protein response (UPR) as an adaptive mechanism to restore 
normal ER function (148).  
 The UPR integrates three primary transduction pathways that transmit 
signals from the ER to the nucleus. Three indepedent transmembrane sensors 
initiate each pathway: PERK, IRE1!, and ATF6. The final outcome of this 
advanced signaling network is the activation of four distinct cellular responses. 
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The first is transcriptional activation of chaperones to enhance an essential ER 
function. The second is translational attenuation to decrease the client load of ER 
lumen proteins. The third is ER-associated degradation (ERAD), where 
terminally misfolded proteins are retrotranslocated into the cytosol and tagged 
for degradation at the proteasome. Finally, in the case where these three adaptive 
outcomes fail to eliminate ER stress, apoptotic pathways are activated (22).  
 The UPR is known to play an important role in the basic physiology of 
several cell types, including B cells, hepatocytes and osteoblasts (149). In fact, it is 
estimated that misfolded proteins constitute upwards of 30% of newly 
synthesized proteins as determined by a variety of cell types, confirming the 
UPR as a fundamental cellular process (150). The β-cell is no exception, with its 
primary function of producing and secreting insulin in response to secretogogue 
stimulation. In order to fulfill this function, the β-cell must maintain constant 
synthesis of insulin and its precursor, proinsulin. Accordingly, the β-cell 
experiences rapid increases in proinsulin synthesis in response to an influx of 
nutrients (53). Any increase in the biosynthetic load of the β-cell could potentially 
result in ER stress, thus hindering proper proinsulin folding in the ER, trafficking 
of proinsulin to the Golgi, and secretion of mature insulin from secretory 
granules (55). This is particularly the case in T2D, where a state of insulin 
resistance imposes a biosynthetic burden on the β-cell.  
 Several mouse models have shown that ER stress in the β-cell 
recapitulates characteristics of T2D (61-64). Very few, however, have contributed 
to our understanding of the particular role of ERAD in glucose homeostasis. We 
have generated and characterized the first mouse model for Sel1L, a gene that 
  55 
encodes a type I ER membrane protein with high abundance in the vertebrate 
pancreas and central nervous system (137). It has been proposed that SEL1L 
facilitates protein-protein interactions and nucleates the ERAD machinery at the 
interface of the ER and cytoplasm (known as the retrotranslocon) (91, 118). This 
complex in its entirety is responsible for identification, translocation, 
ubiquitylation, and ultimate degradation of misfolded proteins. Our global 
knockout demonstrated that a homozygous mutation in Sel1L (Sel1L-/-) causes 
early gestational lethality. We have also previously shown that the complete 
elimination of Sel1L is associated with endogenous ER stress, a defective ERAD, 
and cell death (137). Epithelial cells of the Sel1L-/- pancreatic bud are unable to 
grow and differentiate into β-cells in culture (151). However, heterozygous mice 
(Sel1L+/-) show no prominent developmental phenotype, and also no obvious 
metabolic phenotype on a regular chow diet. 
 Experimental high-fat diets (HFD) have been used to simulate the 
“Western” diet that induces obesity and the complications that are associated 
with it, specifically insulin resistance and T2D. The condition of obesity produces 
ER stress by a global increase in the synthesis of secretory proteins in the body, 
mechanical stress, abnormalities in nutrient availability, and lipotoxicity (37). We 
hypothesize that challenging Sel1L+/- mice with a HFD will lead to enhanced ER 
stress in the β-cell in comparison to the wild-type mice on a HFD.  
 In addition to using a nutritional stress to investigate the specific role of 
Sel1L in the β-cell, we have also generated a conditional mouse model with a β-
cell-specific deletion of Sel1L. These mice have been engineered using the cre-lox 
approach and exhibit RIP-Cre-mediated recombination of a floxed Sel1L allele. By 
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using this model, we can gain insight into the tissue-specific function of SEL1L in 
glucose homeostasis under normal or stressed conditions. 
  
3.3  Materials and Methods 
Mice 
The Sel1L global knockout mice were generated by a gene trap insertion 
(SA-β-geo-polyA) between exons 14 and 15 of chromosome 12. The gene-trapped 
mouse embryonic stem cell line, CA0017 (Sanger Institute Gene Trap Resource), 
was injected into C57BL/6 blastocysts. The resulting chimeric male founders 
were backcrossed to C57BL/6 females to generate heterozygous mice. After 
backcrossing for about 5 generations, Sel1L+/− mice were then intercrossed to 
generate viable Sel1L+/+ and Sel1L+/− mice for these studies.  
Sel1Llox/+ mice were generated by injecting pre-targeted embryonic stem 
cells into C57BL/6 blastocysts. Mice expressing the target vector were bred to 
FLPe transgenic mice, kindly provided by Dr. Paula Cohen. The resulting Sellox/+ 
mice were then bred to homozygosity. Sellox/lox mice were crossed with RIP-Cre 
mice (Jackson Laboratory, B6.Cg-Tg(Ins2-cre)25Mgn/J). Sellox/+; RIP-Cre were 
crossed to Sellox/lox mice to generate Sellox/lox; RIP-Cre mice and littermate controls 
for experiments. A standard PCR was performed on genomic DNA to confirm 
Cre-mediated recombination (Appendix B, Figure a). 
    
All animal experiments were performed in accordance with the Cornell Animal 
Care and Use Guidelines. 
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In Vivo Physiological Studies 
Blood glucose levels were taken at the same time on a weekly basis 
(random or non-fasting blood glucose) or after 8 hours of overnight fasting 
(fasting blood glucose). For the glucose tolerance test (GTT), mice were fasted for 
8 hours and then given an intraperitoneal injection of a sterile solution of glucose 
in phosphate-buffered saline (PBS) at a final concentration of 1 g/kg body 
weight. Blood glucose levels were measured at 0, 15, 30, 60 and 120-minute time 
points. For the insulin tolerance test (ITT), mice were fasted overnight for 8 hours 
and given an intraperitoneal (IP) injection of recombinant insulin in PBS (Eli 
Lilly, 0.75 IU/kg body weight). Blood glucose levels were measured for each 
mouse at 0, 30, 60, 90, and 120-minute time points. The Ascensia ELITE XL 
glucometer and accompanying strips were used for the aforementioned studies. 
Serum insulin was assayed using the ELISA Kit for Rat/Mouse Insulin 
(Millipore) and Mouse Insulin Ultrasensitive ELISA (ALPCO) according to 
manufacturer’s instructions.  
Mice were placed on the research high-fat diet (Harlan Teklad Custom 
Research Diet), consisting of 60.3% fat, 21.3% carbohydrate, and 18.4% protein 
(kcal breakdown), at 6 weeks (conditional knockout mice) or 10 weeks (global 
knockout mice) of age. Food was given ad libitum. For pharmacological 
treatment, 4-phenylbutyric (4-PBA) sodium salt (Scandinavian Formulas) was 
given once a day by oral gavage at a concentration of 1g/kg (global knockout 
mice). For water bottle treatment, 4-PBA sodium salt was dissolved in acidified 
drinking water (1 g/kg/day) and provided to mice starting at 10 weeks of age 
(conditional knockout mice). Bottles were replaced weekly.  
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Islet isolations, Ex Vivo and In Vitro Glucose-Stimulated Insulin Secretion (GSIS) 
Mouse islet isolations were performed as previously described with minor 
modifications (152). Briefly, after sacrifice of each mouse, the pancreas was 
perfused via the common bile duct with 2 mg/ml collagenase (Sigma) in Hank’s 
balanced salt solution (HBSS). The inflated pancreas was excised and incubated 
at 37 °C for 5-8 minutes. The collagenase-digested pancreas was vigorously 
shaken, washed 3 times with 10 ml of ice-cold HBSS, and re-suspended in 1 ml of 
27% Ficoll 400 (Sigma) in HBSS. Islets were hand-picked and washed three times 
with ice-cold 1X HBSS before processing for further analysis.  
Ex vivo GSIS was performed as described previously (153). Briefly, 
isolated islets were cultured overnight in RPMI 1640 medium supplemented 
with 10% FBS, antibiotics, and 10 mM glucose. Approximately 10 islets per well 
were selected in a 24-well dish with Krebs-Ringer bicarbonate buffer (KRBB) 
consisting of (in mM): glucose 2.8, NaCl 130, KCl 4.8, MgSO4 1.2, KH2PO4 1.2, 
CaCl2 2.5, NaHCO3 5.0, and HEPES 10, titrated to pH 7.4 with NaOH and 
supplemented with 1% BSA (Sigma). Islets were cultured for 1 hour at 37°C and 
5% CO2. Islets were then incubated for 30 minutes in either 2.8 and 17.8 mM 
glucose KRBB, after which the supernatants were collected and stored at -80°C 
until assayed for insulin concentration using the Mouse Insulin Ultrasensitive 
ELISA (ALPCO).  
 In vitro GSIS was conducted in stably infected Min6 cells (see Insulinoma 
Cell Lines) using a previously established protocol (154). Briefly, Min6 cells were 
plated at a density of 1 X 106 cells per well in a 6-well plate with standard culture 
media. After induction with doxycycline, the media was removed and cells were 
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washed 2X with KRBB without BSA or glucose. After, cells were equilibrated 
with KRBH containing 1% BSA and 2.8 mM glucose for 30 minutes at 37°C and 
5% CO2. They were then incubated with either 2.8 mM or 17.8 mM glucose for 30 
minutes, after which the supernatants were removed and stored at -80°C until 
assayed for insulin concentration using the ELISA Kit for Rat/Mouse Insulin 
(Millipore).  
The islets or Min6 from each GSIS treatment were centrifuged, washed, 
and resuspended in either RIPA buffer for total protein concentration 
determination or an acid ethanol solution (95% ethanol, 10.2 N HCl in a 50:1 
ratio) for insulin content concentration. Secreted insulin was normalized to islet 
insulin content, which was normalized to the total protein concentration. 
   
Pancreatic Morphology and Immunohistochemistry  
Pancreata were removed and fixed in 4% paraformaldehyde (PFA) at 4° 
overnight, embedded in paraffin blocks, and sectioned at 5-8 µm. For insulin 
immunostaining, sections were rehydrated, blocked for endogenous peroxidase 
activity (3% H2O2), and permeabilized with 0.1% Triton-100 in PBS. After 
blocking with 10% normal donkey serum, guinea pig anti-human insulin (Linco, 
1:1000) was applied overnight at 4°. An HRP-conjugated donkey anti-guinea pig 
immunoglobulin (IgG) secondary antibody (Jackson ImmunoResearch 
Laboratories, 1:500) was applied for 1 hour at room temperature. The ImmPact 
DAB peroxidase kit (Vector Technologies) was used as the substrate. Slides were 
counterstained with hematoxylin (Gill’s, diluted 1:10). β-cell mass was 
determined as previously described (155). Briefly, total pancreatic and β-cell 
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areas were measured using the AxioVision software (Version 4.1). β-cell mass 
(mg) was calculated by multiplying the percentage of β-cell area identified by 
insulin immunostaining with the total pancreatic weight. To determine β-cell 
proliferation, pancreatic sections were co-immunostained with mouse 
monoclonal anti-Ki67 (Vector Laboratories, 1:500) and anti-insulin antibodies. 
Cy3-conjugated donkey anti-mouse and Cy2-conjugated donkey anti-guinea pig 
secondary antibodies (Jackson ImmunoResearch Laboratories, 1:500) were 
applied. Nuclei were counterstained with DAPI. The percentage of Ki67-positive 
cells was derived by dividing the number of Ki67-positive nuclei by the total 
number of counted β-cell nuclei. TUNEL staining was performed according to 
instructions for the Chemicon International Apoptog Peroxidase In Situ 
Apoptosis Detection Kit S7100 (Millipore Corporation). The ImmPact DAB 
peroxidase kit (Vector Technologies) was used as the substrate, and a 
hemotoxylin counterstain (Gill’s, diluted 1:10) was applied. Images were 
acquired using either the Zeiss Axiovert 40 microscope or the Zeiss LSM 510 
Meta confocal microscope.  
  
RNA Extraction and Quantitative Real-Time Reverse Transcription PCR 
RNA was isolated from relevant tissues by the TRIzol-chloroform method. 
RNA quality and concentration was measured using the Agilent 2100 
Bioanalyzer (Agilent Technologies). First-strand cDNA synthesis was performed 
using RT Buffer, dNTPs, DTT, RNAout, and SuperScript III Reverse 
Transcriptase (all Invitrogen). Quantitative PCR was carried out using Power 
SYBR Green PCR Master Mix or iTaq Universal SYBR Green Supermix (Bio-Rad) 
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on an ABI Prism 7000 Sequence Detection System or StepOnePlus Real-Time 
PCR System (Applied Biosystems). PCR primers were designed using the 
PrimerSelect program of Lasergene 7.1 Sequence Analysis Software (DNAstar). 
Final quantification and normalization was determined according to the ''Cq 
calculation method (156). 
 
Insulinoma Cell Lines 
Min6 and INS-1 insulinoma cells were maintained in normal media (Min6: 
Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 1% sodium 
pyruvate, 1% Glutamax, 1% Pen-Strep, and 2 &l β-mercaptoethanol; INS-1: 
Roswell Park Memorial Institute medium with 10 % fetal bovine serum, 1% 
sodium pyruvate, 1% Glutamax, 1% Pen-Strep, and 10 mM HEPES). For 
generation of stable cell lines, cells were seeded at a confluency of 50% and 
infected overnight with inducible lentivirus expressing the reverse tetracycline-
controlled transactivator (rtTA) or rtTA plus DN-SEL1L-GFP. To induce 
expression of transgenes, doxycycline (Sigma) was added into the culture 
medium of Min6 and INS-1 cells (200 &g/ml). 
 
Statistical Analyses 
 Statistical analysis using the student’s T-Test or two-way repeated 
measures ANOVA with Tukey’s HSD post-hoc test where appropriate was 
performed using STATA (v12). 
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3.4  Results 
3.4.1 Sel1L+/- mice are more susceptible to high-fat diet induced hyperglycemia 
 Wild-type (Sel1L+/+) and heterozygote (Sel1L+/-) mice were transitioned 
from a normal chow diet to a high-fat diet (HFD) at 10 weeks of age. The average 
body weights of the two genotypes did not significantly differ or diverge 
throughout the 28-week treatment period (Appendix B, Figure b). However, after 
8 weeks on the HFD, the fasting blood glucose levels of the Sel1L+/- mice were 
significantly higher than those of the Sel1L+/+ mice (Figure 3.1a). Although the 
Sel1L+/+ mice displayed a normal response to the HFD with increasing fasting 
blood glucose levels over time, this rate is higher in the Sel1L+/- mice. Sel1L+/+ and 
Sel1L+/- mice on a HFD also showed a differential metabolic phenotype in other 
respects. After 20 weeks on a HFD, the glucose tolerance test (GTT) revealed a 
higher fasting glucose level for the Sel1L+/- mice in comparison to their wild-type 
counterparts (Figure 3.1b). When injected intraperitoneally with glucose (1 
g/kg), the heterozygous mice were not as efficient as the wild type mice in blood 
glucose uptake. As time elapses, the blood glucose level of the Sel1L+/- mice 
remained consistently higher than the Sel1L+/+ mice. In the Sel1L+/+ mice, blood 
glucose levels fell to fasting levels within 2 hours, the blood glucose levels in the 
Sel1L+/- mice remained high at this time point. We reasoned that glucose 
intolerance could be the result of either insulin resistance or a defect in insulin 
secretion. When injected intraperitoneally with insulin (1 U/kg), blood glucose 
levels in the Sel1L+/+ and Sel1L+/- mice, after 24 weeks on the diet, were not 
significantly different (Figure 3.1c). Interestingly, the fasting serum levels of 
insulin in Sel1L+/- mice on a HFD for 20 weeks were noticeably elevated in 
comparison with the Sel1L+/+ mice (Figure 3.1d). This elevation appears to be a 
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feature of HFD feeding, as there is no difference in fasting serum insulin levels 
between the two genotypes on normal chow (at the same age as the HFD mice).  
We used the glucose-stimulated insulin secretion (GSIS) assay to 
determine β-cell functionality in Sel1L+/+ and Sel1L+/- mice (Figure 3.1e). Islets 
were isolated from mice of both genotypes and incubated in a low glucose 
condition (buffer containing 3 mM glucose) and a high glucose condition (buffer 
containing 30 mM). A 10-fold glucose concentration difference was used to 
provide an adequate level of stress to the haploinsufficient islets, similar to a 
HFD. Basal level and glucose-stimulated insulin secreted into the media were 
measured to give the fold change in GSIS. This value is greatly reduced in Sel1L+/- 
islets, indicating that an inherent insulin secretion defect could explain elevated 
fasting blood glucose levels in the Sel1L+/- mice. 
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Figure 3.1: Sel1L+/- mice on a HFD exhibit a greater degree of hyperglycemia 
and impaired insulin secretion. (a) Fasting blood glucose levels were taken once 
every four weeks for wild-type (n=11) and heterozygote mice (n=17) on a 60% 
high-fat diet (HFD). Treatment started at 10 weeks of age (Week 0). (b) Glucose 
tolerance was assessed using a glucose tolerance test (GTT) in both genotypes 
after 20 weeks of HFD feeding (n=7-8 mice per genotype). (c) Insulin resistance 
was assessed using an insulin resistance test (ITT) in both genotypes after 24 
weeks of HFD feeding, n=7-8 mice per genotype (d) Fasting serum insulin levels 
in Sel1L+/+ (n=9) and Sel1L+/- mice (n=9) on normal chow (NC) and a HFD for 20 
weeks. (e) Fold change in glucose-stimulated insulin secretion (GSIS) in 
pancreatic islets isolated from Sel1L+/+ (n=3) and Sel1L+/- mice (n=4), then 
challenged with 30 mM glucose in vitro. The fold change represents the ratio 
between the media insulin concentration with high glucose (30 mM) to the 
concentration with low glucose (3 mM). *, p<0.05; **, p<0.01. Seen in Figures 1 
and 2 of (157). 
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3.4.2  Sel1L+/- mice exhibit a failure to expand β-cell mass in response to a HFD 
 It is well known that there is an adaptive response to insulin resistance in 
the β-cell. One result of peripheral insulin resistance is an expansion of β-cell 
mass and an increase in β-cell proliferation. Insulin immunostaining of 
pancreatic sections from Sel1L+/+ and Sel1L+/- mice (Figure 3.2a and 3.2b, 
respectively) demonstrated that islets are particularly smaller in the Sel1L+/- mice 
on a HFD (for 20 weeks). The calculated β-cell mass (Figure 3.2c) affirmed that it 
is significantly lower in Sel1L+/- mice. To determine the fundamental cause of this, 
we performed TUNEL staining for apoptosis and Ki67 immunostaining for 
proliferation. The TUNEL analysis revealed no major difference in apoptosis in 
pancreatic sections from each genotype (data not shown). However, we did 
discover that there were less Ki67-positive β-cells in the pancreatic sections from 
HFD-fed Sel1L+/- mice (Figure 3.2e) versus the HFD-fed Sel1L+/+ mice (Figure 
3.2d). Co-staining with insulin and counterstaining with DAPI in these sections 
allowed us to identify proliferating β-cells and quantify them for each genotype 
(Figure 3.2f). These results indicate that Sel1L+/- mice are incapable of expanding 
their β-cell mass in response to peripheral insulin resistance, as seen in wild-type 
mice.   
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Figure 3.2: Sel1L+/- mice on a HFD have less β-cell mass due to reduced 
proliferation of β-cells. These images show insulin staining of islets, indicated in 
brown, in representative pancreatic sections from (a) Sel1L+/+ and (b) Sel1L+/- mice 
after 20 weeks on a HFD (10X magnification). (c) β-cell mass at this time point 
was calculated by using the ratio of the positively stained insulin areas to the 
area of the pancreatic section, then multiplying by the weight of the whole 
pancreas (n= 7 mice per genotype).  Immunostaining for Ki67 (red), insulin 
(green) and DAPI (blue) is seen in representative pancreatic sections from (d) 
Sel1L+/+ and (e) Sel1L+/- mice after 20 weeks on a HFD (40X magnification). The 
white arrows indicate staining of Ki67 β-cells as a marker of proliferation. (f) 
Quantification of the percentage of Ki67-positive β-cells in pancreatic sections 
from Sel1L+/+ and Sel1L+/- mice (n=3 mice per genotype) on a HFD (20 weeks). *, 
p<0.05, **, p<0.01. Seen in Figure 2 of (157).  
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3.4.3  Endoplasmic reticulum stress is present in pancreatic islets and other 
peripheral tissues of HFD-fed Sel1L+/- mice 
 We previously reported that the complete loss of Sel1L in mice  (Sel1L-/-) 
causes ER stress throughout the organism (137). We therefore evaluated the 
possible presence of ER stress in the tissues of HFD-fed Sel1L+/- mice that are 
most affected by the onset of obesity. In islets isolated from Sel1L+/+ and Sel1L+/- 
mice and cultured overnight under low glucose conditions (10 mM), there was 
no significant difference in gene expression of UPR markers such as Bip, Herp, 
Chop, and p58IPK (Figure 3.3a). However, a high glucose condition (30 mM) 
resulted in a marked upregulation of UPR markers in the islets of Sel1L+/- mice, in 
comparison to wild-type controls (Figure 3.3b). To verify the evident ER stress, 
we asked whether a chemical chaperone known as 4-PBA (0.02 M) can promote 
proper protein folding. Islets isolated from Sel1L+/- mice were incubated with 
either 4-PBA or DMSO in high glucose, and gene expression was again assessed 
and compared between the two samples (Figure 3.3c). The presence of 4-PBA 
significantly reduced ER stress in Sel1L+/- islets. To demonstrate an in vivo effect, 
Adam Francisco orally administered 4-PBA or PBS daily to Sel1L+/+ and Sel1L+/- 
mice (HFD, 20 weeks) for one week. By the end of the treatment period, the 4-
PBA-treated Sel1L+/- mice showed a significant reduction in their fasting blood 
glucose levels in comparison to the PBS-treated controls (157). Together, these 
results imply that the hyperglycemia in HFD-treated Sel1L+/- mice is dependent 
on ER stress. 
 ER stress has also been implicated in the development of insulin resistance 
in diet-induced obesity models. Although the insulin tolerance test showed no 
significant difference in response to exogenous insulin administration, the fasting 
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serum insulin levels of Sel1L+/- mice on a HFD were higher than those seen in the 
Sel1L+/+ mice (Figure 3.1d). This points to some degree of insulin resistance in the 
heterozygotes challenged with a HFD. Therefore, in collaboration with Dr. Haibo 
Sha from Dr. Ling Qi’s lab, we prepared protein lysates from the livers of Sel1L+/+ 
and Sel1L+/- mice after 20 weeks on the HFD. Through western blotting, we 
observed markedly increased expression of UPR markers such as BIP, 
CALNEXIN, and EIF2! in the livers of the HFD-fed Sel1L+/- mice (157). Therefore, 
ER stress is pervasive in many tissues of the Sel1L+/- mice on a HFD. 
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Figure 3.3: Key UPR markers are upregulated in the islets of Sel1L+/- mice on a 
HFD. Quantitative real-time PCR (qPCR) was used to assess the expression of 
UPR markers in cDNA from islets isolated from Sel1L+/+ and Sel1L+/- mice (n=3 
sets of islets per genotype) and cultured in (a) 10 mM glucose and (b) 30 mM 
glucose overnight. In (c), qPCR analysis of UPR markers in islets isolated from 
Sel1L+/- mice and treated in high glucose conditions with a chemical chaperone, 4-
PBA (0.02 M), or DMSO as a control (n=3 sets of islets per treatment). *, p<0.05; 
**, p<0.01. Seen in Figure 3 of (157). 
 
3.4.4  Interference of SEL1L function in vitro results in impaired glucose-
stimulated insulin secretion and proliferation 
 To further address the mechanism by which Sel1L maintains β-cell 
homeostasis, we developed a tetracycline-inducible lentivirus that expresses a 
dominant negative form of SEL1L (DN-SEL1L). This construct contains a 
deletion at the C-terminal end of the SEL1L protein and a GFP tag. We used this 
lentivirus in the insulinoma cell lines, MIN6 (mouse-derived) and INS-1 (rat-
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derived). In Min6 cells that are stably infected with DN-SEL1L-GFP, the addition 
of doxycycline (dox) to the media promotes the expression of the deletion 
mutant, seen in Figure 3.4a. After confirming the expression of the construct 
through western blotting and fluorescence microscopy, we used the stably 
infected Min6 cells cultured with and without dox to determine the effects of 
SEL1L disruption on β-cell function. In vitro GSIS confirms that there was a 
failure to completely respond to a high glucose concentration (stimulated) in 
Min6 cells expressing DN-SEL1L (Figure 3.4b).  
We also evaluated the role of Sel1L in β-cell proliferation using INS-1 cells. 
We generated INS-1 cell lines stably expressing the rtTA regulatory proteins (as a 
virus control) and rtTA and DN-SEL1L. In the cells expressing rtTA and DN-
SEL1L (+), there was increased protein expression of the chaperone BIP within 12 
hours of dox incubation versus the control cells (-) (Figure 3.4c). Throughout the 
dox treatment, BIP levels remained consistently higher in cells expressing DN-
SEL1L. Furthermore, Adam Francisco used cell counting and thymidine 
incorporation to assess cell proliferation in these cell lines (157). The proliferation 
rate of the INS-1 cells stably infected with DN-SEL1L was significantly lower 
than that of INS-1 cells infected with rtTA alone (both cell lines incubated with 
dox in the media).  
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Figure 3.4: Insulinoma cell lines ectopically expressing a dominant-negative 
form of SEL1L show evidence of defective insulin secretion and ER stress. 
Min6 cells were stably infected with a tetracycline-inducible lentivirus expressing 
a dominant negative form of SEL1L (DN-SEL1L) tagged to GFP. (a) Western blot 
analysis of infected Min6 cells in the absence and presence of doxycycline (Dox), 
and probed for GFP and tubulin as a loading control. (b) In vitro glucose-
stimulated insulin secretion in Min6 cells without DN-SEL1L and with DN-
SEL1L (n=3 independent experiments). The basal condition was low glucose (2.8 
mM) and the stimulated condition was high glucose (17.8 mM). (c) Western blot 
of protein lysate from INS-1 cells with and without stable expression of the dox-
inducible lentiviral transgene, DN-SEL1L-GFP. The BIP protein was probed for 
after 12, 24, and 48 hours of dox induction. Tubulin is shown as a loading 
control. *, p<0.05. Seen in Figure 4 of (157).  
 
3.4.5  Selective deletion of Sel1L in β-cells leads to early-onset hyperglycemia in 
mice 
 Although using a diet-induced obesity model with the Sel1L heterozygous 
mice was insightful, we wanted to further investigate the physiological role of 
Sel1L in β-cells. To address this, we generated mice with floxed Sel1L alleles (loxP 
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sites flanking exon 6 of the Sel1L gene). Mice homozygous for this floxed allele 
(Sellox/lox) were then crossed to mice expressing the Cre recombinase, driven by the 
rat insulin promoter (RIP-Cre). Using this line of Cre mice, genetic deletion of 
Sel1L would be expected primarily in β-cells of these mutant mice (Sellox/lox; RIP-
Cre) (158).  
The metabolic phenotype of Sellox/lox; RIP-Cre mice were characterized in 
comparison to their Sellox/lox and Sellox/+; RIP-Cre littermate controls. Random blood 
glucose levels were consistently higher in Sellox/lox; RIP-Cre mice, starting as early 
as 2 weeks of age (Figure 3.5a). This trend is sustained into adulthood and the 
difference is evident even in the absence of a nutrient or chemical stress on these 
mice. Similarly, fasting blood glucose levels were elevated in Sellox/lox; RIP-Cre 
mice as early as 6 weeks of age (Figure 3.5b). To measure the in vivo response of 
β-cells to glucose, we performed a glucose tolerance test (GTT) at various ages. 
The GTT at 6 weeks of age revealed that mutant mice are severely glucose 
intolerant, as seen by their reduced ability to clear the injected glucose as 
efficiently as the control mice (Figure 3.5c). At 12 weeks of age, the GTT indicated 
that Sellox/lox; RIP-Cre mice reach higher blood glucose levels post-injection than 
seen in the 6-week GTT (Figure 3.5d). The Sellox/+; RIP-Cre mice at this age appear 
to exhibit a similar response to the glucose injection at both ages. This evidence 
suggests that glucose intolerance is exacerbated over time in Sellox/lox; RIP-Cre 
mice. 
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Figure 3.5: Mice with the conditional deletion of Sel1L in β-cells display early 
onset hyperglycemia and glucose intolerance. (a) Random blood glucose levels 
of wild-type (Sellox/lox), heterozygote (Sellox/+; RIP-Cre), and mutant (Sellox/lox; RIP-
Cre) mice were measured on a weekly basis between 2 and 24 weeks of age 
(n=18-23 mice per genotype). (b) Fasting blood glucose levels were measured for 
Sellox/lox and Sellox/lox; RIP-Cre mice on a weekly basis between 5 and 24 weeks of age 
(n=5 mice per genotype). Glucose tolerance was assessed using a glucose 
tolerance test (GTT) in Sellox/lox (n=4), Sellox/+; RIP-Cre (n=7) and Sellox/lox; RIP-Cre 
(n=8) mice at (c) 6 weeks of age and (d) 12 weeks of age. *, p<0.05; **, p<0.01. 
 
3.4.6  A high-fat diet exacerbates hyperglycemia and glucose intolerance in 
Sellox/lox; RIP-Cre mice  
 In our earlier studies, the high-fat diet (HFD) was used as an exogenous 
stress on the Sel1L+/- mice. Administering a diet high in fat content leads to 
obesity. Obesity is associated with insulin resistance, and insulin resistance 
prompts insulin production in β-cells. We reasoned that in mice with a β-cell-
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specific deletion of Sel1L, a high-fat diet would be particularly detrimental to β-
cell function. Indeed, a high-fat diet, started at 6 weeks of age, caused a 
substantial increase in fasting blood glucose levels in Sellox/lox; RIP-Cre mice. This 
was seen just after one week of treatment (Figure 3.6a). Over the course of the 
treatment period, the glucose levels increased steadily to values averaging close 
to 300 mg/dl in the mutant mice at the 14-week termination point. Furthermore, 
the GTT in Sellox/lox and Sellox/lox; RIP-Cre mice, after 6 weeks on the HFD, showed a 
significant difference in glucose tolerance between the two genotypes. The 
Sellox/lox; RIP-Cre mice reached higher blood glucose levels post-injection, and fail 
to clear this blood glucose over the course of the 2-hour period (Figure 3.6b).    
a      b 
  
Figure 3.6: A HFD worsens the metabolic phenotype in Sellox/lox; RIP-Cre mice. 
Wild-type (Sellox/lox, n=8), heterozygote (Sellox/+; RIP-Cre, n=11), and mutant (Sellox/lox; 
RIP-Cre, n=10) mice were started on a 60% high-fat diet at 6 weeks of age (Week 
0). (a) Fasting blood glucose levels were taken for each genotype throughout the 
14-week treatment period. (b) Glucose tolerance was assessed with a glucose 
tolerance test (GTT) in Sellox/lox (n=4) and Sellox/lox; RIP-Cre (n=5) mice after 6 weeks 
on a HFD. *, p<0.05; **, p<0.01. 
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3.4.7  The absence of Sel1L in β-cells causes improper trafficking and secretion of 
insulin 
 Loss of β-cell mass was partially responsible for the greater degree of 
hyperglycemia observed in Sel1L+/- mice on a HFD. To determine if a similar 
observation could be made in Sellox/lox; RIP-Cre mice, we used insulin 
immunostaining of pancreatic sections from Sellox/lox and Sellox/lox; RIP-Cre mice 
(Figure 3.7a and 3.7b, respectively). This illustrated that there was no obvious 
change in β-cell mass due to the loss of Sel1L. Quantification of β-cell mass in 
each genotype (Figure 3.7c) confirmed there was no significant difference at 6 
weeks of age. Immunohistochemical analysis using TUNEL assay revealed that 
there are no detectable differences in β-cell apoptosis at this age (data not 
shown). Furthermore, Ki67 immunostaining of pancreatic sections from each 
genotype also indicated that β-cell proliferation is normal in Sellox/lox; RIP-Cre mice 
(see Figure 4.4e). 
 Since there is no β-cell loss or defect in the ability of β-cells to proliferate in 
Sellox/lox; RIP-Cre mice, we next wanted to investigate the functionality of β-cells. 
Islets were isolated from Sellox/lox and Sellox/lox; RIP-Cre mice and cultured in vitro in 
a low glucose concentration condition (2.8 mM) and a high glucose concentration 
condition (17.8 mM). Even in the low glucose condition, islets from Sellox/lox; RIP-
Cre mice secreted less insulin in comparison to wild-type islets. While islets from 
Sellox/lox mice showed a normal increase in insulin secretion in response to the high 
glucose concentration, islets from Sellox/lox; RIP-Cre mice failed to respond. 
 To further understand this marked insulin secretion defect, we used co-
immunostaining of pancreatic sections to localize proinsulin to cellular 
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compartments. In both wild-type and mutant islets, proinsulin co-localizes with 
GM130, a member of the Golgin family of proteins and a component of the Golgi 
apparatus (Figure 3.7e and 3.7f) (159). However, mutant islets displayed more 
intense proinsulin staining (Figure 3.7f), suggesting that there was greater 
expression in comparison to wild-type islets. This accumulation of proinsulin 
was not confined to the Golgi, as proinsulin also co-localized with the ER marker 
calnexin in mutant but not wild-type β-cells (Figure 3.7h and 3.7g, respectively). 
Together, the intensity and localization of proinsulin expression in mutant islets 
indicates that the anterograde trafficking of this precursor is stymied due to the 
loss of Sel1L. 
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Figure 3.7: Sellox/lox; RIP-Cre mice have significantly reduced glucose-stimulated 
insulin secretion due to a proinsulin trafficking defect. These images show 
insulin staining of islets, indicated in brown, in representative pancreatic sections 
from (a) Sellox/lox and (b) Sellox/lox; RIP-Cre mice at 6 weeks of age (10X 
magnification). (c) β-cell mass at this time point was calculated by using the ratio 
of the positively stained insulin areas to the area of the pancreatic section, then 
multiplying by the weight of the whole pancreas (n= 5 mice per genotype). (d) 
Glucose-stimulated insulin secretion was assayed using an insulin ELISA for 
islets isolated from Sellox/lox (n=4) and Sellox/lox; RIP-Cre (n=4) mice and cultured in 
vitro. Immunostaining of a representative pancreatic section are pictured from (e) 
Sellox/lox and  (f) Sellox/lox; RIP-Cre mice; from left to right, proinsulin (green), GM130 
(red), and the merged image with DAPI (nuclei, blue). Similarly, 
immunostaining of representative islets from (g) Sellox/lox and  (h) Sellox/lox; RIP-Cre 
mice; from left to right, proinsulin (green), calnexin (red), and the merged image 
with DAPI (nuclei, blue). p *, p<0.05; **, p<0.01. 
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Figure 3.7, Continued: 
 
 
 
3.4.8  Administration of 4-PBA promotes reduction of hyperglycemia in Sellox/lox; 
RIP-Cre mice.  
 We first affirmed the presence of ER stress in β-cells lacking Sel1L by using 
quantitative real-time RT- PCR of UPR markers in isolated islets from Sellox/lox and 
Sellox/lox; RIP-Cre mice (Figure 3.8a). This expression analysis revealed a consistent 
upregulation of UPR markers, such as Erdj3, Chop, and Xbp1s in the islets of the 
mutant mice. 
 This observation indicated that β-cells lacking Sel1L are subject to ER 
stress. We wanted to use an in vivo approach to determine if the ER stress is 
causing elevated blood glucose levels. To test this, we placed wild-type and 
mutant mice on a 4-PBA water bottle treatment (1 g/kg B.W.) at 10 weeks of age. 
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4-PBA is a chemical chaperone that has been previously reported to promote 
intracellular protein folding, trafficking, and secretion in conditions of ER stress. 
The 4-PBA treatment was effective in lowering fasting blood glucose levels in 
Sellox/lox; RIP-Cre mice after 10 weeks. As 4-PBA has been established to mitigate 
ER stress in vivo and in vitro, and 4-PBA can reduce fasting blood glucose levels 
in our mutant mice, we speculate that ER stress is responsible for the 
hyperglycemic phenotype in Sellox/lox; RIP-Cre mice. 
 
  a         b 
   
Figure 3.8: 4-PBA can rescue hyperglycemia in Sellox/lox; RIP-Cre mice. (a) 
Quantitative real-time PCR (qPCR) was used to assess the expression of UPR 
markers in cDNA from islets isolated from Sellox/lox and Sellox/lox; RIP-Cre mice (n=4-
5 sets of islets per genotype). In (b), fasting blood glucose levels during water 
bottle administration of the chemical chaperone 4-PBA (1 g/kg) to Sellox/lox and 
Sellox/lox; RIP-Cre mice (n=5 mice per genotype), were observed starting at 10 
weeks of age (Week 0). *, p<0.05; **, p<0.01. 
 
3.5  Discussion 
 It is abundantly clear that abnormalities in insulin sensitivity and β-cell 
function contribute to hyperglycemia in T2D. The HFD and conditional mouse 
models for Sel1L insufficiency implicate that defective ER-associated degradation 
may play a critical role in susceptibility to this metabolic disorder. Haploid 
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insufficiency of SEL1L and obesity, caused by a HFD, contribute to the 
development of metabolic characteristics of diabetes. Sel1L+/- mice on a HFD 
display elevated blood glucose levels, in comparison to HFD-fed wild-type mice, 
starting at 8 weeks of HFD treatment. They also exhibit a greater degree of 
glucose intolerance and reduced in vitro glucose-stimulated insulin secretion 
(GSIS) from islets. Interestingly, Sel1L+/- mice on a HFD have reduced β-cell mass 
at later stages of HFD treatment (20 weeks) in comparison to controls. This 
reduction in mass was found to be the result of inadequate proliferative capacity 
of β-cells in response to insulin resistance. In the presence of high glucose, islets 
isolated from Sel1L+/- mice show evident upregulation of UPR markers compared 
to wild-type islets. Correspondingly, incubation with the chemical chaperone 4-
PBA reverses induction of the UPR in Sel1L+/- islets in a high glucose condition. In 
vitro studies in insulinoma cell lines expressing a dominant-negative form of 
SEL1L reinforce the impaired GSIS and reduced proliferation observed in vivo.   
 The selective deletion of Sel1L in β-cells (Sellox/lox; RIP-Cre) also confirms an 
integral role for SEL1L in β-cell function. Sellox/lox; RIP-Cre mice exhibit 
hyperglycemia (on a normal diet) and severely impaired glucose intolerance that 
worsens over time. These metabolic parameters are exacerbated when Sellox/lox; 
RIP-Cre mice are administered a high-fat diet. While there is no observable 
difference in β-cell mass between Sellox/lox; RIP-Cre mice and Sellox/lox mice (up to 12 
weeks of age), defective GSIS and glucose intolerance are observed in the Sellox/lox; 
RIP-Cre mice. Further, β-cells of Sellox/lox; RIP-Cre mice have an accumulation of 
proinsulin in the ER which obstructs the insulin secretory pathway. UPR markers 
are upregulated in the islets of Sellox/lox; RIP-Cre mice, and administration of 4-PBA 
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in drinking water can reduce fasting blood glucose levels over time, suggesting 
ER stress is the presumable cause of this cellular and metabolic phenotype. 
 Various mouse and human genetic models have demonstrated that 
increased ER stress induces β-cell dysfunction and T2D. For example, mutations 
in Perk, Eif2", p58IPK, and Wfs1 in mice lead to hyperglycemia due to defective 
intracellular trafficking of ER cargo proteins, insufficient insulin secretion, 
and/or β-cell death (61, 62, 160, 161).  These studies substantiate the role of the 
UPR in β-cell function and survival. While many of these models focus on the 
regulation of proinsulin and insulin synthesis and translational attenuation, the 
importance of the ERAD mechanism in pancreatic β-cells has not been 
extensively studied. However, two mouse models support the function of ERAD 
in normal β-cell physiology. The Akita mouse, characterized by expression of 
misfolded insulin, exhibits hyperglycemia, decreased insulin secretion, and 
progressive apoptosis of β-cells over time (57). With regard to ERAD 
components, Akita mice have been observed to have relatively higher transcript 
levels of Bip, Hrd1, and Sel1L in the pancreatic islets compared to their wild-type 
counterparts (117). Also, transgenic mice for the human islet amyloid polypeptide 
(hIAPP) gene provide critical insight into the failure of the UPR to prevent 
intracellular oligomerization of this amyloidogenic protein. Male mice exhibit a 
diabetic phenotype beginning between 4 to 8 weeks of age, and death around 16 
weeks. This diabetic phenotype includes β-cell death associated with decreased 
circulating insulin levels, hyperglycemia, and abnormal intracellular aggregates 
of hIAPP (162). An impaired ubiquitin-proteasomal pathway in the β-cells 
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contributes to the apoptosis in this mouse model (163). Furthermore, islets from 
patients with T2D show dysfunctional ubiquitin-proteasomal degradation, due 
in part to overexpression of misfolded human islet amyloid polypeptide (hIAPP) 
(164). This dysfunction was found to be mediated by a deficiency in ubiquitin 
carboxyl-terminal hydrolase L1 (UCH-L1) protein levels.  
 Interestingly, phenotypic similarities were observed between ERAD-
deficient and autophagy-deficient mice. Autophagy is the engulfment of 
misfolded proteins or protein aggregates within double-membrane vesicles that 
subsequently fuse to a lysosome, containing the proper enzymes for degrading 
the contents (103). Knockout of autophagy-related protein 7 (ATG7), a factor for 
autophagy, in β-cells of mice results in a level of hyperglycemia that is 
comparable to what we observe in our conditional mouse model. Moreover, 
there is decreased β-cell mass, compromised β-cell function, and an accumulation 
of ubiquitylated aggregates in the Atg7-β-cell-deficient mice (165). When 
challenged with a high-fat diet, these mice fail to expand β-cell mass due to 
increased apoptosis and degeneration of β-cells (166).  
 Intriguingly, although the Sel1L+/- mice on a HFD and Sellox/lox; RIP-Cre mice 
both display an apparent defect in insulin secretion in response to glucose, they 
both also have elevated serum insulin levels (Figure 3.1a and 4.4a). 
Hyperinsulinemia is typically an indication of insulin resistance. It has been 
reported that an increase in JNK activity (through nutrient-induced ER stress in 
mice) causes an increase in serine phosphorylation of insulin receptor substrate-1 
(IRS-1), which in turn reduces insulin receptor signaling and contributes to 
insulin resistance in peripheral tissues (37). Essentially, ER stress may provide an 
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important link between obesity and T2D. Although the insulin tolerance test 
(ITT) in heterozygote mice on a HFD indicates that there is no significant change 
in insulin sensitivity, we did see an upregulation of UPR markers at the protein 
level in their livers. Further biochemical and molecular studies would be 
required to determine what role SEL1L has in regulating insulin sensitivity in 
peripheral tissues. 
 One notable difference between the HFD and conditional mouse models 
for Sel1L is related to β-cell mass. Sel1L+/- mice on a HFD have a markedly 
reduced β-cell mass in comparison to wild-type mice on a HFD. This is attributed 
to a decrease in proliferation of β-cells and not to an increase in apoptosis. In 
Sellox/lox; RIP-Cre mice, there is no change in β-cell mass due to the genetic loss of 
Sel1L. Instead, there is a striking defect in GSIS in the β-cells. This differential 
phenotype at the level of the β-cell points to diverse roles for SEL1L in β-cell 
function and proliferation. β-cell mass is not altered at 8 weeks of age for HFD-
fed Sel1L+/- mice, but fasting blood glucose levels are significantly elevated. This 
leads to the possibility that the observed hyperglycemia is due to an inherent 
secretion defect. Only at later stages of the HFD treatment do we observe 
insufficient expansion of β-cell mass. A HFD has been shown to have lipotoxic 
effects in β-cells in vivo and in vitro. Chronically elevated levels of circulating free 
fatty acids (FFAs) are putative mediators of β-cell dysfunction and death in T2D 
(167, 168). Palmitate, a saturated long-chain FFA, induces ER stress in both clonal 
and primary murine and human β-cells, and preferentially activates both PERK 
and IRE1! pathways (72, 169). Several studies indicate that palmitate triggers ER 
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stress in β-cells through perturbations in ER Ca2+ balance and disruption of 
secretory pathways (71, 170). Therefore, in the condition of long-term 
overnutrition, haploinsuffieciency of SEL1L function generates some level of ER 
stress to affect β-cell proliferation.  However, increased β-cell death is not seen in 
Sel1L+/- mice on a HFD, indicating that adaptive mechanisms in the cells must be 
preventing the initiation of apoptotic pathways. ER stress can decrease β-cell 
proliferation via induction of the UPR, when translational attenuation limits cell 
growth capabilities. IRE1! activity is known to mediate apoptotic pathways in 
response to ER stress, but has also recently been shown to inhibit proliferation 
through downregulation polo-like kinase 1 (PLK1), an early trigger for G2/M 
transition (171). β-cell mass is known to be modulated by several factors, 
including by increased signaling by insulin and/or insulin-like growth factor-1 
(IGF-1) (146). SEL1L could be a direct or indirect participant in regulating insulin 
signaling to influence β-cell proliferation. Perhaps certain proteins in these 
signaling pathways are regulated by ERAD, which is presumably compromised 
in our heterozygote mouse model for Sel1L.  
 Trafficking of proteins from the ER to the Golgi apparatus is required for 
efficient ERAD (172). Conversely, it seems that an intact ERAD is necessary for 
proper protein folding and trafficking. In yeast, mutations in ERAD components 
such as Der1p and Hrd3p lead to morphological changes in the ER and Golgi 
and a slower maturation rate of wild-type secretory proteins (173). In Sel1L+/- 
mice on a HFD and Sellox/lox; RIP-Cre mice, loss of Sel1L contributes to an inability 
to secrete insulin and this in turn contributes to hyperglycemia. A defective 
ERAD complex in the β-cells of these mice causes an accumulation of proinsulin 
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within the ER and delayed maturation of insulin. Both of these models also have 
reduced total pancreatic insulin content in comparison to their respective 
controls (Appendix B, Figures f and g). A similar observation was made in islets 
and insulinoma cell lines with loss of Perk function. These cells are reported to 
have impaired anterograde protein trafficking and are unable to retrotranslocate 
and degrade known ERAD substrates. In our Sel1L-deficient models, impaired 
trafficking could be a consequence of or a cause of ER stress. Although 4-PBA is 
able to rescue hyperglycemia in both the Sel1L+/- mice on a HFD and Sellox/lox; RIP-
Cre mice, this chemical compound has properties that improve both ER stress 
and secretory protein trafficking. Therefore, further studies would be required to 
dissect the general role of SEL1L in ER homeostasis and a potential more specific 
role in ER to Golgi trafficking.  
 Taken together, these data reinforce an instrumental role for Sel1L in ER 
and β-cell homeostasis. SEL1L is required for maintaining normal glucose 
tolerance. At a cellular level, SEL1L is necessary for secretion of insulin in 
response to glucose and for expansion of β-cell mass in response to HFD-induced 
insulin resistance. Therefore, the ERAD process is indispensible for glucose 
homeostasis. Our data demonstrates that ER stress has an important causal role 
in the pathogenesis of T2D. Administration of 4-PBA, to mitigate ER stress in the 
β-cell, could be an effective therapy to enhance insulin secretion and improve β-
cell survival in this disease.   
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CHAPTER 4: THE ROLE OF Sel1L IN HYPOTHALAMIC NEURONS AND 
ENERGY HOMEOSTASIS 
 
4.1  Abstract 
 The hypothalamus is a major site of integration of peripheral and central 
signals to maintain energy balance. Inaction of hypothalamic  neurons to leptin 
and insulin (leptin/insulin resistance) is the cause of obesity. Cellular and 
molecular evidence points to an emerging role for endoplasmic reticulum (ER) 
stress in mediating leptin resistance in the hypothalamus. To further address this 
potential role, we investigated the contribution of an ER-specific pathway, 
known as ER-associated degradation (ERAD), in energy homeostasis. The mouse 
Suppressor-enhancer-lin 12-1-Like (Sel1L) gene encodes an ER transmembrane 
protein known to nucleate the ERAD translocation machinery at the interface of 
the ER and cytosol. We have previously reported that global disruption of Sel1L 
leads to early embryonic lethality in mice. As discussed in Chapter 3, we 
generated conditional knockout mice with selective deletion of Sel1L in β-cells. 
The RIP-Cre transgene, however, was also found to be expressed in the  
hypothalamus. Starting at around 12 weeks of age, the male mutant mice (Sellox/lox; 
RIP-Cre), showed a pronounced increase in body weight, food intake, and 
adiposity over time in comparison to control mice (Sellox/lox and Sellox/+; RIP-Cre). 
Furthermore, Sellox/lox; RIP-Cre mice had elevated fasting leptin and insulin levels 
and an impaired response to the administration of exogenous leptin, suggestive 
of leptin resistance. ER stress was present in the hypothalami of Sellox/lox; RIP-Cre 
mice, particularly in the arcuate nucleus and paraventricular nucleus, as 
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determined by quantitative RT-PCR of UPR markers. The arcuate nucleus also 
showed increased expression of the Pomc transcript and unchanged expression of 
Npy transcript. Starting at 10 weeks of age, ongoing administration of the 
chemical chaperone 4-PBA in drinking water prevented weight gain in Sellox/lox; 
RIP-Cre mice. Finally, administration of 4-PBA via the intracerebroventricular 
(ICV) route reduced food intake and body weight in Sellox/lox; RIP-Cre mice at 23 
weeks of age, indicating that ER stress is mediating the hyperphagic obesity in 
these mice. Taken together, these data strongly suggest that Sel1L has a crucial 
role in the central nervous system to regulate energy homeostasis. Further 
investigations are needed to elucidate the molecular mechanisms that underlie 
the observed SEL1L action in the brain. 
 
4.2  Introduction 
 Obesity has become a major global public health concern in recent 
decades. Currently, over one-third of adults in the US are obese and the rate at 
which both adults and children worldwide are becoming overweight or obese is 
staggering (174). Mortality rates associated with being overweight and obese 
have also seen an upward trend due to related risks such as hypertension, 
diabetes and hypercholesterolemia. Manifestation of obesity and weight gain has 
been shown to be multifaceted, ranging from genetic predisposition to 
socioeconomic status to age. The genetic determinants of body weight regulation 
in humans, however, still remain poorly understood.  
 Weight balance in mammals involves the integration of signals from the 
pancreas, adipose tissue, gastrointestinal tract, and brain, among several other 
organs. The brain, in particular, controls food intake and energy expenditure 
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through leptin signaling in the hypothalamus. Leptin, a hormone secreted from 
adipose tissue, enters the brain and acts on its receptors in the mediobasal 
hypothalamus to exert its anorexigenic effects. In particular, the arcuate nucleus 
(ARC) has high expression of Ob-Rb (the predominant long-form of the leptin 
receptor) in two distinct neuronal populations: NPY/AGRP and POMC/CART. 
NPY/AGRP co-expressing neurons promote food intake while POMC/CART co-
expressing neurons inhibit food intake through melanocortin signaling in 
secondary neurons (175). Leptin and insulin behave reciprocally on these 
neurons so their effect in response to nutritional status is decreased energy intake 
and increased energy expenditure to produce a sense of satiety.  
 An obese state is characterized by overconsumption and an expansion of 
adipose tissue, leading to hyperleptinemia. Despite this elevation of leptin in the 
blood and consequently in cerebrospinal fluid, the aforementioned hypothalamic 
neurons cannot respond appropriately to restore energy balance. This condition 
is referred to as “leptin resistance,” and is a main target for unraveling the 
cellular and molecular basis of obesity. The two hypotheses that have received 
the most attention in this regard are the impairment of leptin transport to its 
targets in the brain or a defect in the intracellular Ob-Rb signaling cascade (46, 
176). High-fat diet (HFD) murine models have been used to resolve the 
interaction between polygenic and environmental factors that contribute to leptin 
resistance. Diet-induced obese (DIO) mice are also systems to explore leptin 
function and compromised leptin and insulin signaling in obesity.  Evidence 
from several HFD studies has implicated a critical role for endoplasmic 
reticulum (ER) stress in the pathogenesis of diet-induced obesity (47, 48, 50).  
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Disequilibrium in misfolded or unfolded proteins and the folding capacity 
of the ER generates “ER stress.” ER stress elicits the UPR as an adaptive 
mechanism to restore normal ER function (148). The UPR is a signaling network 
that integrates 3 distinct branches, each initiated by an ER-localized “stress 
sensor”: PERK, IRE1!, and ATF6. Together, the UPR regulates the expression of 
various genes to maintain homeostasis in the ER or induce apoptosis in 
conditions where ER stress cannot be mitigated. Homeostatic mechanisms of the 
UPR include an attenuation of protein translation and increased ERAD to 
remove toxic proteins from the ER lumen. ER stress has been implicated as a 
causal factor in many pathologies, including metabolic disease, inflammation, 
neurodegeneration, and cancer (177). 
Although previous studies have described ER stress as a principle 
mediator of central insulin and leptin resistance in the context of a HFD and 
overnutrition, they have not addressed ER stress as it relates to the genetic 
component of obesity. Compelling scientific evidence has led to the belief that 
the propensity to become obese is largely genetically determined (178, 179). This 
is supported by the fact that weight loss in obese individuals is often met with 
compensatory genetic responses, leading to an increase in hunger and decrease 
in activity. For this reason, most people who lose weight by dieting eventually 
regain it within a short period of time (180, 181).   
In the present study, we explore the contribution of the UPR and 
specifically ERAD in the regulation of weight balance. We developed a 
conditional mouse model for Suppressor-enhancer-lin 12-1-Like (Sel1L), a gene that 
encodes a multimodular protein with an established role in ERAD. SEL1L is 
speculated to function in protein-protein interactions at the interface of the ER 
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lumen and cytosol, where it facilitates the ubiquitylation and extrusion of 
misfolded proteins. In the first mouse model for Sel1L, we have previously 
shown an essential role for this ERAD factor in development and glucose 
homeostasis (137, 157). With our current conditional knockout mice, we were 
able to effectively delete Sel1L in the hypothalamus. Here, we reveal for the first 
time a novel mechanism by which ERAD regulates energy homeostasis and by 
which ER stress contributes to the pathogenesis of obesity.   
 
4.3  Materials and Methods 
Mice 
For the conditional deletion of Sel1L, embryonic stem cells were 
purchased by the UC Davis KOMP repository and injected into C57BL/6 
blastocysts. Mice expressing the target vector were bred to FLPe transgenic mice, 
kindly provided by Dr. Paula Cohen. The resulting Sellox/+ mice were bred to 
homozygosity. Sellox/lox mice were crossed with RIP-Cre mice (Jackson Laboratory, 
B6.Cg-Tg(Ins2-cre)25Mgn/J). Sellox/+; RIP-Cre were crossed to Sellox/lox mice to 
generate Sellox/lox; RIP-Cre mice and littermate controls for experiments. A 
standard PCR was performed on genomic DNA to confirm Cre-mediated 
recombination (Appendix C, Figure a). 
 
All animal experiments were performed in accordance with the Cornell Animal 
Care and Use Guidelines. 
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In vivo physiological studies 
 Body weights of mice were recorded on a weekly basis starting one week 
after birth. For the insulin tolerance test (ITT), mice were fasted overnight for 8 
hours and given an intraperitoneal (IP) injection of recombinant insulin in PBS 
(Eli Lilly, 0.75 IU/kg B.W.). Blood glucose levels were measured for each mouse 
at 0, 30, 60, 90, and 120-minute time points. The Ascensia ELITE XL glucometer 
and accompanying strips were used for blood glucose measurement. For the 
leptin resistance test, recombinant leptin (A.F. Parlow, National Hormone & 
Peptide Program, 3 mg/kg B.W.) was delivered to mice via IP injection at 9 A.M. 
and 6 P.M. for 4 days. Body weight, food intake and random blood glucose were 
measured each day. Serum insulin and serum leptin were assayed using the 
Mouse Insulin Ultrasensitive ELISA (ALPCO) and the Leptin (Mouse/Rat) 
ELISA (ALPCO), respectively, according to manufacturer’s instructions.  
For 4-PBA treatment, 4-phenylbutyric sodium salt (Scandinavian 
Formulas) was dissolved in acidified drinking water (1 g/kg/day) and provided 
to mice starting at 10 weeks of age. Bottles were replaced weekly.  
 Intracerebroventricular (ICV) cannulation was performed as previously 
described (182, 183). Following implantation of the cannulas, mice recovered for 
5 days. Baseline measurements were taken for 3 days prior to injections with 4-
PBA (1 &l of 10 mg/ml or 10 &g). Body weight and food intake were recorded 
daily. 
 For activity (energy expenditure) data collection, the Oxymax 
Comprehensive Lab Animal Monitoring System (CLAMS) for Rats and Mice 
(Columbus Instruments) was used (courtesy of Dr. Ling Qi and the Department 
of Animal Science). Pair-feeding was performed with individually housed Sellox/lox 
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and Sellox/lox; RIP-Cre mice between 16 and 18 weeks of age.  Sellox/lox mice were fed 
ad libitum and their food intake was measured every 24 hours. The same amount 
of food was provided to age- and weight-matched Sellox/lox; RIP-Cre mice. Body 
weights were measured each day.  
 
 All physiological studies used male mice.  
 
Adiposity and Micro computed tomography (Micro CT) analysis 
 Adiposity was measured at 6 weeks and 32 weeks of age by dissecting 
and weighing the paired epididymal, subcutaneous, and retroperitoneal white 
adipose depots for each mouse. The adiposity percentage for each mouse 
represents the collective weight of these depots as a ratio to the total body 
weight. 
 Micro CT scans of 1-year old Sellox/lox and Sellox/lox; RIP-Cre mice were 
performed at the Cornell Micro CT and Nano CT Imaging Facility using the GE 
eXplore CT120 (50 &M resolution). Analysis was performed as described 
previously (184). OsiriX (v5.5) imaging software was used for the 3D rendering 
and quantification of regions of interest. Total fat volume was determined as an 
absolute value and not a percentage.   
  
Immunohistochemistry 
  To determine β-cell proliferation, pancreatic sections were co-
immunostained with mouse monoclonal anti-Ki67 (Vector Laboratories, 1:500) 
and anti-insulin antibodies. Cy3-conjugated donkey anti-mouse and Cy2-
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conjugated donkey anti-guinea pig secondary antibodies (Jackson 
ImmunoResearch Laboratories, 1:500) were applied. Nuclei were counterstained 
with DAPI. The percentage of Ki67-positive cells was derived by dividing the 
number of Ki67-positive nuclei by the total number of counted β-cell nuclei. 
 
RNA Extraction and Quantitative Real-Time Reverse Transcription PCR 
For isolation of the whole hypothalamus, mice were decapitated and their 
brains were quickly extracted and stored on dry ice for 5 minutes. A mouse brain 
slicer matrix (Zivic Instruments) was used to separate the hypothalamus from 
other brain tissue. For the isolation of hypothalamic regions, brains were 
extracted, immediately embedded in OCT, frozen on dry ice, and stored at -80 
until further use. Specific regions were isolated using a crystat and cylindrical 
brain punchers based on the Mouse Brain Stereotaxic Atlas (Academic Press, 
Second edition). For these isolations, punches from each region were pooled 
from two independent mice per sample. RNA was isolated from hypothalamic 
regions and the hypothalamus by the TRIzol-chloroform method. RNA quality 
and concentration was measured using the Agilent 2100 Bioanalyzer (Agilent 
Technologies). First-strand cDNA synthesis was performed using RT Buffer, 
dNTPs, DTT, RNAout, and SuperScript III Reverse Transcriptase (all Invitrogen). 
Quantitative PCR was carried out using Power SYBR Green PCR Master Mix or 
iTaq Universal SYBR Green Supermix (Bio-Rad) on an ABI Prism 7000 Sequence 
Detection System or StepOnePlus Real-Time PCR System (Applied Biosystems). 
PCR primers were designed using the PrimerSelect program of Lasergene 7.1 
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Sequence Analysis Software (DNAstar). Final quantification and normalization 
was determined according to the ''Cq calculation method (156). 
 
Statistical Analyses 
 Statistical analysis using the student’s T-Test or two-way repeated 
measures ANOVA with Tukey’s HSD post-hoc test where appropriate was 
performed using STATA (v12). 
 
4.4  Results 
 
4.4.1  The hypothalamus-specific deletion of Sel1L contributes to the increased 
weight gain over time on a normal chow diet 
 Body weights were monitored on a weekly basis in the three genotypes 
(Sellox/lox, Sellox/+; RIP-Cre, and Sellox/lox; RIP-Cre) starting at 2 weeks of age. For both 
males and females, there appeared to be relatively normal fluctuations in body 
weight between the three genotypes, while maintained on a normal chow diet, 
for the first 12 weeks of age (Figure 4.1a and 4.1b). However, after this time point 
there was a steady increase in the body weights of the Sellox/lox; RIP-Cre mice. The 
divergence was slower in males than in females, with the body weights of the 
male mice reaching significantly higher values at 18 weeks of age, and female 
mice at 13 weeks of age (p<0.05). By 32 weeks of age, Sellox/lox; RIP-Cre mice 
continued to gain weight in comparison to their control littermates (Figure 4.1c). 
This difference is exemplified in Figure 4.1d and 4.1e. At 12 months of age, the 
discrepancy in mass is exceptional, as depicted through Micro CT imaging and 
computer-assisted analysis of adiposity (Figure 4.1f and 4.1g). The body weights 
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of Sellox/lox; RIP-Cre mice at this age are, on average, about 73% higher than Sellox/lox 
mice.       
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Figure 4.1: Sellox/lox; RIP-Cre mice gain significant weight over time on a normal 
chow diet. Shown here are the body weights of (a) male and (b) female mice of 
each genotype (n=8-12 mice per genotype per sex) from 2 to 24 weeks of age 
(p<0.05 after week 18 for males and week 13 for females). (c) Body weights were 
measured for each sex at 32 weeks of age. (d) and (e) Pictures representing an 
average Sellox/lox; RIP-Cre (left) and Sellox/lox (right) mouse were taken at 32 weeks of 
age. Micro CT images show visceral and subcutaneous fat depots highlighted in 
red for (f) Sellox/lox and (g) Sellox/lox; RIP-Cre mice at approximately 12 months of age. 
(h) Quantification (to be added). *, p<0.05; **, p<0.01.  
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Figure 4.1, Continued: 
 
 
 
4.4.2  Increased adiposity in Sellox/lox; RIP-Cre mice is due to hyperphagia 
 To quantify adiposity at 32 weeks of age for the Sellox/lox; RIP-Cre mice 
versus the controls (collectively Sellox/lox and Sellox/+; RIP-Cre mice), various white 
fat depots were isolated from each mouse and weighed (Figure 4.2a). Adiposity 
was also quantified at 6 weeks of age for each genotype, and no significant 
difference was observed (data not shown). The mutant mice, on average, 
displayed adiposity that was nearly twice greater than that seen in the control 
mice. The expansion of subcutaneous, retroperitoneal, epicardial (Figure 4.2a and 
4.2b), and epididymal fat depots was clearly seen in Sellox/lox; RIP-Cre mice. 
Histological analysis of subcutaneous adipose tissue in Sellox/lox and Sellox/lox; RIP-
Cre mice (Figure 4.2e and 4.2f, respectively) indicated that there are enlarged 
adipocytes in the mutant mice.  
Increased adiposity led us to investigate feeding behavior and energy 
expenditure as possible sources of this deviance. Mice between the ages of 7 and 
11 weeks, when the body weights are similar between the genotypes, did not 
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show a genotype-dependent difference in food intake (Figure 4.2g). However, 
Sellox/lox; RIP-Cre mice between the ages of 12 and 16 weeks had significantly 
higher food intake in comparison to their littermate controls (Figure 4.3h). 
Energy expenditure was assessed using a lab animal monitoring system for 
Sellox/lox and Sellox/lox; RIP-Cre mice at 12 weeks of age, prior to the divergence in 
body weights. Oxygen consumption and the respiratory exchange ratio (RER), as 
indicators of gas exchange and therefore energy expenditure, were not 
significantly different between the genotypes (Figure 4.2i). Therefore, only 
hypothalamic feeding circuits are altered in Sellox/lox; RIP-Cre mice, and the 
increase in body weight is primarily attributed to hyperphagia. Pair-feeding 
studies with mice at 16 weeks of age also confirmed this finding (Appendix C, 
Figure b). 
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Figure 4.2: Obesity in Sellox/lox; RIP-Cre mice is due to hyperphagia. (a) Various 
white fat depots were excised and their collective weight as a percentage of the 
total body weight per mouse was used to assess adiposity in Sellox/lox; RIP-Cre mice 
and control (Sellox/lox and Sellox/+; RIP-Cre) mice at 32 weeks of age (n=7-8 
mice/genotype). Pictures of the thoracic cavity are seen for a (b) wild-type and 
(c) mutant mouse at 32 weeks of age, as well as (d) epididymal fat pads from a 
wild-type (left) and mutant (right) mouse. Next, H&E staining of subcutaneous 
fat pad sections from a (e) Sellox/lox; RIP-Cre and (f) Sellox/lox mouse are depicted (10X 
magnification). (g) Food intake per day was measured in mice of each genotype 
between the ages of 7 and 11 weeks and (h) between the ages of 12 and 16 weeks 
(n=6-7 cages per genotype). (i) Metabolic cages were used to determine oxygen 
consumption (VO2, seen above) as a reflection of energy expenditure in the mice 
at 12 weeks of age (n=4 cages per genotype).   
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Figure 4.2, Continued: 
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4.4.3 Sellox/lox; RIP-Cre mice are leptin resistant prior to weight gain 
 Leptin plays a key role in regulating energy intake and expenditure. Its 
presence in the central nervous system, specifically the mediobasal 
hypothalamus, is proportional to its plasma concentration. We therefore 
examined fasting serum leptin levels in Sellox/lox and Sellox/lox; RIP-Cre mice at 
various ages (Figure 4.3a). A normal increase in serum leptin levels was observed 
in Sellox/lox mice, due to a correlated increase in adiposity with age. Serum leptin 
levels in Sellox/lox; RIP-Cre mice were significantly higher than those seen in Sellox/lox 
mice at each age. At 6 and 12 weeks of age, there was no significant difference in 
body weights between the genotypes, yet still elevated serum leptin levels in 
Sellox/lox; RIP-Cre mice. By 32 weeks of age, an accumulation of adipose tissue 
contributed to serum leptin levels that are on average about 2.5 times higher in 
Sellox/lox; RIP-Cre mice than in control mice. 
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 To further assess leptin resistance, we administered leptin (I.P., 2.5 mg/kg 
B.W.) twice daily to Sellox/+; RIP-Cre and Sellox/lox; RIP-Cre mice and measured body 
weight and food intake each day. Administration of a supraphysiological dose of 
recombinant leptin caused reductions in weight and food consumption in control 
mice over a 2 to 3 day period. As seen in Figure 4.3b and 4.3c, Sellox/lox; RIP-Cre 
mice had a blunted response to the exogenous leptin versus the Sellox/+; RIP-Cre 
mice. Together, hyperleptinemia and a diminished response to leptin constitute a 
state of leptin resistance in Sellox/lox; RIP-Cre mice. 
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Figure 4.3: Sellox/lox; RIP-Cre mice have severe leptin resistance. (a) Serum from 
fasting Sellox/lox and Sellox/lox; RIP-Cre mice at various ages was collected and 
assayed for leptin concentration using an ELISA (n=6-8 mice per genotype). Mice 
of each genotype (Sellox/+; RIP-Cre and mutants, n=7-8 mice per genotype) were 
given I.P. injections leptin (2.5 mg/kg B.W.) twice daily for 4 days. Changes in 
(b) weight and (c) food intake were monitored over this time. *, p<0.05; **, 
p<0.01, ***, p<0.001. 
     
4.4.4  Increased fat content manifests in apparent insulin resistance in Sellox/lox; 
RIP-Cre mice 
   The RIP-Cre transgene is also expressed in the pancreatic β-cells of mice. 
Therefore Sel1L is deleted in the β-cells of Sellox/lox; RIP-Cre mice. As discussed 
previously in Chapter 3, Sellox/lox; RIP-Cre mice are hyperglycemic and their β-cells 
have a conspicuous defect in glucose-stimulated insulin secretion. Furthermore, 
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Sel1L+/- mice (global knockout) have reduced proliferation of β-cells in response 
to HFD-induced insulin resistance. Since insulin is an important adiposity signal 
in the central nervous system, and since Sel1L deletion is expected in β-cells, we 
wanted to determine the degree of insulin resistance and its effect in the β-cells of 
Sellox/lox; RIP-Cre mice. 
 As with leptin, fasting serum insulin levels were assayed in Sellox/lox and 
Sellox/lox; RIP-Cre mice at 6, 12 and 32 weeks of age (Figure 4.4a). Whereas the 
serum insulin concentration in control mice remained relatively constant with 
age, the serum insulin concentration in Sellox/lox; RIP-Cre mice was increased with 
age. Again, as seen with the serum leptin levels, there was elevated serum 
insulin at 6 and 12 weeks of age, which is prior to the period of weight gain in 
Sellox/lox; RIP-Cre mice. To physiologically assess insulin resistance, we performed 
an insulin tolerance test on mice at 24 weeks of age (Figure 4.4b). Mice were 
injected with recombinant insulin (IP, 0.75 IU/kg B.W.) and blood glucose levels 
were monitored at intervals within a 2-hour post-injection period. Sellox/lox mice 
and Sellox/+; RIP-Cre mice responded normally to the exogenous insulin with a 
modest decline in blood glucose levels. Sellox/lox; RIP-Cre mice displayed an 
anomalous response to the insulin injecton, with average relative blood glucose 
levels that significantly increased during the post-injection period. 
Given that the ITT revealed severe insulin resistance in Sellox/lox; RIP-Cre 
mice, we expected there would be an expansion of β-cell mass in response to this 
resistant state. Insulin immunostaining of pancreatic sections from Sellox/lox and 
Sellox/lox; RIP-Cre mice demonstrated that β-cell mass was significantly higher in 
the Sellox/lox; RIP-Cre mice at 32 weeks of age (Appendix C, Figure d). We also 
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performed Ki67 and insulin co-immunostaining on pancreatic sections from each 
genotype at this same age to evaluate proliferation of β-cells. There were 
significantly more Ki67-positive, and thus proliferating, β-cells in the Sellox/lox; RIP-
Cre pancreata (Figure 4.4d) than in the Sellox/lox pancreata (Figure 4.4c). 
Quantification of Ki67-positive β-cells in each genotype at 6 weeks of age 
indicated that there was no significant difference in proliferative cells between 
the genotypes at this time (Figure 4.4e). At 32 weeks of age, the percentage of 
Ki67-positive β-cells in the Sellox/lox; RIP-Cre pancreata was comparable to that 
seen at 6 weeks of age (for both genotypes). While wild-type mice show a normal 
decline in β-cell proliferation with age, the development of insulin resistance 
does indeed prompt β-cell replication in the mutant. Therefore, the absence of 
Sel1L in β-cells of Sellox/lox; RIP-Cre does not hinder β-cell proliferation in response 
to insulin resistance.     
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Figure 4.4: Sellox/lox; RIP-Cre mice maintain a normal response to insulin 
resistance in the β-cell. (a) Serum from fasting Sellox/lox and Sellox/lox; RIP-Cre mice 
at various ages was collected and assayed for insulin concentration using an 
ELISA (n=6-8 mice per genotype). (b) At 24 weeks of age, insulin tolerance was 
assessed in Sellox/lox, Sellox/+; RIP-Cre and Sellox/lox; RIP-Cre mice through an ITT (n=5-
8 mice per genotype). Immunostaining for Ki67 (red), insulin (green) and DAPI 
(blue) is seen in representative pancreatic sections from (c) Sellox/lox and (d) Sellox/lox; 
RIP-Cre mice at 32 weeks of age (40X magnification). (e) Quantification of the 
percentage of Ki67-positive β-cells in pancreatic sections from Sellox/lox and Sellox/lox; 
RIP-Cre mice (n=4 mice per genotype) at 6 and 32 weeks of age. *, p<0.05, **, 
p<0.01, ***, p<0.001. 
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Figure 4.4, Continued: 
        e 
 
 
 
4.4.5  ER stress in the hypothalami of Sellox/lox; RIP-Cre mice causes weight gain 
 We hypothesized that ER stress, caused by defective ERAD, may be 
responsible for the impaired hypothalamic function. To understand the 
molecular basis of peripheral leptin and insulin resistance in Sellox/lox; RIP-Cre 
mice, we utilized quantitative real-time PCR (qPCR) to evaluate the expression of 
UPR markers in hypothalami excised from Sellox/lox and Sellox/lox; RIP-Cre mice at 12 
weeks of age (Figure 4.5a). There was an expected reduction in the expression of 
Sel1L in the mutant mice, yet a significant increase in the relative expression of 
Erdj3, Chop, Xbp1s and Bip. These genes are classified as UPR markers because 
they are upregulated in response to ER stress and collectively play an important 
role in restoration of ER homeostasis.  
 In collaboration with Dr. Colin Young from Dr. Robin Davisson’s lab, we 
extracted specific regions of the hypothalamus and performed qPCR in order to 
characterize and localize the metabolic functions of Sel1L. In analyzing the 
arcuate nucleus (ARC) of each genotype, the relative gene expression of Pomc 
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(which is ultimately processed posttranslationally to !-MSH) was significantly 
higher in the mutants than in the wild-type controls (Figure 4.5b). Expression of 
the orexigenic neurotransmitter Npy was unchanged while the expression of the 
UPR marker Erdj3 was highly upregulated in the ARC of mutant mice (Figure 
4.5b). In comparing gene expression in the paraventricular nucleus (PVN) of each 
genotype, Erdj3, Xbp1s, and Chop were significantly higher in mutant mice than 
in the control mice (Figure 4.5c). These data altogether suggest that there is 
evident ER stress in key regions of the hypothalamus that are likely responsible 
for modulating energy balance through leptin signaling.  
We next assessed whether ER stress is causing leptin resistance and 
ultimately weight gain. To test this, we placed wild-type and mutant mice on a 4-
PBA water bottle treatment (1 g/kg B.W.) at 10 weeks of age. 4-PBA in drinking 
water has previously been shown to ameliorate ER stress in various brain regions 
of rodents and therefore has the ability to cross the blood brain barrier (185). In 
our study, treatment with 4-PBA in the drinking water effectively prevented 
weight gain in Sellox/lox; RIP-Cre mice (Figure 4.5d). The significant divergence in 
weights between the genotypes was normally seen around 18 weeks of age 
(corresponding to 8 weeks of 4-PBA treatment). The body weights of the mutant 
mice were similar to those of the wild-type mice throughout the course of the 
treatment, and this trend is sustained until the termination point (14 weeks). 
Also in collaboration with Dr. Colin Young, intracerebroventricular (ICV) 
cannulas were instrumented into Sellox/lox and Sellox/lox; RIP-Cre mice at 22 weeks of 
age. At this age, the body weights of mutant mice are on average 15 g more than 
that of wild-type mice. Daily ICV injections of 4-PBA (20 &g) resulted in modest 
weight reduction (3 to 4 g) in Sellox/lox; RIP-Cre mice, and no effect on the body 
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weights of the Sellox/lox mice throughout the 12-day injection period (Figure 4.5e). 
Sellox/lox; RIP-Cre mice also showed a reduction in food intake (data not shown), 
indicating that relief of ER stress can partially rescue the energy imbalance in 
Sellox/lox; RIP-Cre mice.   
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Figure 4.5: ER stress causes disturbances in energy balance in Sellox/lox; RIP-Cre 
mice. (a) Gene expression of Sel1L and various UPR markers was analyzed using 
quantitative real-time PCR (qPCR) on total hypothalamic cDNA from Sellox/lox and 
Sellox/lox; RIP-Cre mice (n=4 per genotype). UPR marker and neuropeptide 
expression in each genotype (n=6 per genotype), specifically in the (b) arcuate 
nucleus and the (c) paraventricular nucleus, was also examined using qPCR. In 
(d), body weight during water bottle administration of the chemical chaperone 4-
PBA (1 g/kg) to Sellox/lox and Sellox/lox; RIP-Cre mice (n=5 mice per genotype), was 
observed starting at 10 weeks of age (Week 0). (e) 4-PBA (10 &g) was also 
administered daily through an intracerebroventricular (ICV) cannula in wild-
type and control mice (n=4 mice per genotype) at 23 weeks of age and changes in 
body weight were measured over an 8 day period.  *, p<0.05; **, p<0.01. 
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4.5  Discussion 
 Obesity coincides with a state of central and peripheral insulin and leptin 
resistance. The fundamental causes of this pathophysiological state are 
unknown. Our data from the hypothalamus-specific deletion of Sel1L in mice 
collectively suggest a plausible genetic predisposition that manifests in obesity 
and related disorders. Sellox/lox; RIP-Cre mice develop robust obesity over time. 
Prior to significant weight gain, Sellox/lox; RIP-Cre mice are hyperleptinemic and 
hyperinsulinemic, and resistant to the anorexigenic effects of exogenous leptin. 
Furthermore, the leptin resistance appears to only affect food intake, as energy 
expenditure is not significantly different between Sellox/lox; RIP-Cre mice and wild-
type mice. Analysis of UPR gene expression, also prior to phenotypic changes in 
weight, confirms the presence of ER stress in the hypothalamus of Sellox/lox; RIP-
Cre mice. Administration of 4-PBA, a chemical chaperone, in drinking water 
prevents the onset of weight gain in Sellox/lox; RIP-Cre mice, implicating a 
preventative role for this drug in our mouse model for obesity. Additionally, 
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delivery of 4-PBA directly to hypothalamic areas (ICV route) results in the 
reduction of body mass in overweight Sellox/lox; RIP-Cre mice, suggesting a 
potential therapeutic use for this drug.  
  The elevated serum insulin and leptin levels at 6 weeks of age in Sellox/lox; 
RIP-Cre mice are of particular interest (Figure 4.4a and Figure 4.3a, respectively). 
First, the insulin tolerance test (ITT) reveals that at this stage, mutant mice have a 
normal response to insulin (Appendix B, Figure d). Second, assessment of 
adiposity in the Sellox/lox; RIP-Cre mice at 6 weeks of age is comparable to that seen 
in age-matched Sellox/lox mice (appendix). As previously elaborated on (Chapter 3), 
Sel1L is also deleted in β-cells of Sellox/lox; RIP-Cre mice, leading to hyperglycemia 
and reduced insulin secretion. Due to elevated blood glucose levels at an early 
age, Sellox/lox; RIP-Cre mice may maintain higher circulating levels of insulin as a 
physiological adaptation. Although higher levels of leptin are typically 
associated with an increase in fat mass, leptin secretion may be alternatively 
affected in this hyperinsulinemic state. Altered glucose metabolism and serum 
insulin have been shown to be important determinants of leptin secretion in vivo 
(186, 187). Alternatively, discrete changes in adiposity that are undetectable by 
our method of measurement may account for elevated leptin levels. Further 
studies at the level of the adipocyte or the use of a more sensitive method to 
assess adiposity are needed to explain these phenomena.   
 The administration of 4-PBA to Sellox/lox; RIP-Cre mice implicates a causal 
role for ER stress in the hypothalamus as a key mediator of the development of 
leptin resistance and obesity. The absence of SEL1L function throughout the 
hypothalamus causes inadequate ERAD and compromises the UPR’s adaptive 
  119 
capabilities. This is the likely mechanism of sustained ER stress. As alluded to in 
the introduction, several previous studies in diet-induced and genetic models for 
obesity demonstrated that there is a link between ER stress and leptin resistance. 
HFD-fed mice as well as ob/ob mice show increased ER stress is in their 
hypothalami in comparison to lean controls (47). ER stress in the hypothalamus 
causes leptin resistance in lean mice, as assessed by a decrease in downstream 
markers of leptin signaling such as STAT3 phophorylation and neuropeptide 
expression. In accordance with this, chemical chaperones such as 4-PBA and 
tauroursodeoxycholic acid (TUDCA), are able to decrease ER stress and improve 
leptin signaling in vitro and in vivo. Overnutrition caused by a HFD has also been 
shown to lead to activation of the IKK/NF#B inflammatory pathway, which is 
mediated by diet-induced hypothalamic ER stress (50). Furthermore, IKK/NF#B 
activation contributes to central leptin and insulin resistance by promoting the 
expression of Socs3, an inhibitor of leptin and insulin signaling.   
 The Sel1L-deficient mice phenocopy, to a certain degree, mice with 
disrupted autophagy. Autophagy is the engulfment of misfolded proteins or 
protein aggregates within double-membrane vesicles that subsequently fuse to a 
lysosome, containing the proper enzymes for degrading the contents (103). 
Knockout of ATG7, a factor for autophagy, in POMC neurons results in 
hyperphagia, increased body weight, and glucose intolerance (188, 189). All of 
these parameters are exacerbated when these mice are challenged with a HFD. 
The loss of autophagy in POMC neurons is associated with perturbed axonal 
projections and impaired !-MSH production and secretion, both of which are 
proposed mechanisms for perturbed energy balance in these mice. These results 
reinforce the importance of the protein quality control in hypothalamic neurons.  
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 Our qPCR results showing gene expression in the ARC (Figure 4.5b) 
suggest that leptin signaling in this region is not compromised, as Pomc mRNA 
levels are upregulated in the mutant mice. This observation suggests that leptin 
signaling is mostly retained in first-order neurons of the ARC. This does not, 
however, exclude the possibility that the POMC protein could be affected 
posttranslationally by ER stress. The POMC protein undergoes cleavage in 
secretory vesicles to generate several nascent hormones. Although !-MSH has an 
established role in regulating feeding behavior, other hypothalamic POMC 
products (ACTH, β-endorphin) have important roles in the immune, 
integumentary and reproductive systems (190). We did not observe any 
dysfunctions related to these systems in Sellox/lox; RIP-Cre mice, providing some 
evidence that POMC processing is unaffected.  
 The use of RIP-Cre transgenic mice contributes a level of complexity in 
determining the molecular basis of disease in Sellox/lox; RIP-Cre mice. Various 
reporter lines have confirmed that Cre-mediated recombination occurs 
throughout the hypothalamus in addition to β-cells (158). The absolute neuronal 
populations that are affected by this recombination have not yet been elucidated. 
Several mouse lines in the RIP-Cre background are characterized by the 
development of obesity, often with altered β-cell morphology and function. 
These models include those for Irs2, Stat3, and Tsc1 (191-193). Together, these 
studies substantiate the expression of RIP-Cre in neurons essential for nutrient 
homeostasis.  
 Therefore, the fact that Sel1L is deleted throughout the hypothalamus 
precludes our ability to identify a specific mechanism and site for energy 
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imbalance in Sellox/lox; RIP-Cre mice. Our results, however, provide some basis for 
focusing on the PVN. Because immediate leptin signaling in the ARC leads to 
elevated Pomc expression in accordance with elevated circulating leptin in 
mutant mice, it is reasonable to assume a secondary neuron defect is responsible 
for leptin resistance. The relative expression of Sel1L in the PVN and 
ventromedial hypothalamus (VMH) are the lowest amongst several brain regions 
we examined in Sellox/lox; RIP-Cre mice compared to their wild-type counterparts 
(Appendix C, Figure c). This implies these regions could be important sites of 
dysfunction in our mutant mouse model. Lesions in the PVN and VMH of 
rodents independently and synergistically produce hyperphagic obesity while on 
normal chow or a HFD (194). Neurons of the PVN synthesize and secrete several 
neuropeptides that have been shown to reduce food intake and body weight, 
such as corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone 
(TRH), and oxytocin (195-197). Similarly, brain-derived neurotrophic factor 
(BDNF) in the VMH acts downstream of melanocortin-4 receptor (MC4R) 
signaling to inhibit food intake (198). These positive mediators of weight balance 
could be disrupted in the presence of ER stress to produce this increased energy 
intake and obesity in Sellox/lox; RIP-Cre mice. 
 It is notable that Sellox/lox; RIP-Cre mice have elevated food intake, but 
unaffected energy expenditure (Figure 4.2i). This may also reflect a PVN-specific 
defect. Mice heterozygous for Sim1, encoding a transcription factor, are 
hyperphagic with unaltered energy expenditure (199). These mice also have less 
neuronal cell mass particularly in the PVN. Therefore, loss of functional neuronal 
cells in the PVN predominantly increases appetite and does not influence energy 
expenditure in this model for obesity.  
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 It has also been demonstrated through cre-lox engineering that MC4Rs in 
the PVN control food intake, and that MC4Rs elsewhere control energy 
expenditure (200). Several studies implicate that MC4R could be another 
probable candidate for susceptibility to ER stress in Sellox/lox; RIP-Cre mice. To 
date, MC4R variants are the most common genetic cause of human obesity 
described (17). Humans and mouse models with MC4R deficiency experience 
increased appetite and develop severe obesity over time (201). In childhood 
obesity-associated heterozygous MC4R variants, there is intracellular retention of 
the receptor and less cell surface expression (202). These obesity-linked variants 
of MC4R are also retained in the ER when ectopically expressed in immortalized 
neurons, causing an increase in the expression of ER chaperones, increased ER-
associated degradation, and decreased expression of the receptor at the plasma 
membrane (52). Treatment with 4-PBA in vitro restores the receptor to the cell 
surface and is also able to rescue the function of one variant. 
It is noteworthy that SEL1L may confer susceptibility to obesity in 
humans. The SEL1L gene in humans is located on chromosome 14q24.3-31 in 
what is referred to as a “genome desert.” Previous genome-wide association 
studies (GWAS) have reported chromosome 14q31 as a locus harboring a single-
nucleotide polymorphism (SNP) associated with increased abdominal fat (and 
therefore weight circumference) in obese populations (203, 204). Although these 
studies have identified the gene at this locus as Neurexin 3 (NRXN3), other 
GWAS and molecular studies have not been able to confirm NRXN3 as an 
obesity-associated variant (205). SEL1L is located in close proximity to NRXN3 on 
chromosome 14. More importantly, our studies indicate that SEL1L is a more 
feasible candidate gene in this chromosomal region, particularly associated with 
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excess abdominal fat in obese individuals. Interestingly, in addition to the locus 
at chromosome 14q31, MC4R has also been identified as a locus associated with 
weight circumference.  
In summary, we have identified SEL1L as a novel regulator of energy 
homeostasis. SEL1L and ERAD are imperative for leptin signaling in the 
hypothalamus. In the absence of SEL1L, the development of ER stress contributes 
to dysregulation of energy balance and ultimately results in hyperphagic obesity. 
ER stress could be an important therapeutic target for obesity in the future. 
Further studies are required, especially in the paraventricular nucleus, to 
determine the mechanisms by which SEL1L affects the degradation, secretion, 
and localization of factors related to energy balance.   
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CHAPTER 5: GENERAL DISCUSSION 
5.1  Working Model 
 The broad goal of this dissertation is to determine the physiological role of 
SEL1L in the whole organism, with an emphasis in glucose and energy 
homeostasis. This was based on the hypothesis that the loss of ERAD in β-cells 
and hypothalamic neurons can causes ER stress and cellular dysfunction in T2D. 
In Chapter 2, we show evidence from our Sel1L global knockout mouse model 
that attests to the essential role for SEL1L in development. Our embryological 
and in vitro data show that Sel1L is required for ER homeostasis, cell growth and 
viability, efficient ERAD, and secretion. We use this as the cellular and molecular 
basis for understanding the more tissue-specific functions of SEL1L. Specifically, 
we explore these functions in tissues that are known to participate in the 
pathogenesis of T2D: the pancreas and brain. In Chapter 3, studies with 
heterozygous mice on a HFD as well as mice with a β-cell-specific deletion of 
Sel1L demonstrate that Sel1L is required for normal glucose tolerance and 
glucose-stimulated insulin secretion. In the HFD model, Sel1L is necessary for 
proliferation of β-cells in response to diet-induced insulin resistance. In the 
conditional knockout mouse model, it is clear that Sel1L plays an important role 
in ER to Golgi trafficking of proinsulin. Finally, our conditional knockout model 
also features the hypothalamus-specific deletion of Sel1L. In Chapter 4, our data 
suggests that Sel1L is necessary for the hypothalamic regulation of body mass, 
and in particular leptin signaling. Taken together we have developed a general 
working model to illustrate the potential consequences of loss of Sel1L on 
metabolic homeostasis (Figure 5.1): 
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Figure 5.1: Loss of Sel1L and the pathogenesis of T2D. A working model linking 
the absence of Sel1L and ERAD complex to the pathogenesis of Type 2 Diabetes 
through cellular defects at the level of the β-cell and hypothalamic neurons in 
Sellox/lox; RIP-Cre mice. 
 
Previous investigations point to several other diverse mechanisms of β-
cell failure. Potential causes include glucolipotoxicity, mitochondrial 
dysfunctions (and reactive oxygen species), amyloid deposition, and 
inflammation. Literature also provides evidence for a substantial cellular and 
molecular influence on insulinemia and insulin resistance. Lipotoxicity, cortisol 
and inflammation, and alterations in glucose transporter type 4 (GLUT4), along 
with overnutrition, are associated with a failure to respond to insulin. Overall, 
this dissertation supports a causal role for ER stress in both β-cell dysfunction 
and the development of insulin resistance. As Figure 5.1 depicts, our data 
consistently reinforces that the lack of Sel1L is associated with defective ERAD 
and ER stress. This is evident in our studies with the whole embryo, β-cells and 
hypothalamic neurons. In the β-cell, ER stress arises from a decreased capacity of 
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the ER to respond to glucose stimulation and maintain proinsulin production. 
This manifests in impaired insulin secretion, which constitutes β-cell dysfunction 
and ultimately leads to a failure to control blood glucose levels. In the 
hypothalamus, ER stress ultimately leads to leptin resistance and contributes to 
increased fat content and insulin resistance. As described in the first introductory 
chapter, insulin resistance coinciding with reduced β-cell secretion or mass leads 
to T2D. 
 
5.2  Future Directions 
Sellox/lox; RIP-Cre mice represent a novel model for T2D. However, given the 
brain and pancreas expression of the Cre transgene, it is difficult to dissect 
glucose and energy phenotypes. An adipoinsular axis has been described, in 
which insulin and leptin are involved in a hormonal feedback loop (206). This 
axis can perpetuate obesity and diabetes when dysregulated. Insulin, as an 
anabolic hormone, increases body fat and stimulates the production of leptin. 
Leptin suppresses insulin secretion by its action in the hypothalamus as well as 
in β-cells, and improves insulin sensitivity in peripheral tissues (207). 
Hypothalamic insulin signaling can also decrease food intake and increase 
energy expenditure, and has also been shown to inhibit hepatic glucose 
production (208, 209). In order to distinguish the cell-specific roles of Sel1L, Cre 
lines that are mostly β-cell-specific and hypothalamus-specific must be used. For 
example, MIP-Cre and POMC-Cre mice would be plausible options.  
Our current 4-PBA rescue experiments have not been able to confirm that 
the deletion of Sel1L in β-cells contributes primarily to the glucose phenotype, 
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and the deletion of Sel1L in the hypothalamus to the weight phenotype. 
However, daily ICV administration of 4-PBA did not significantly alter fasting or 
non-fasting blood glucose levels in mutant mice over the 8-day period (data not 
shown). Injections for a longer period of time or perhaps at a higher dose may 
eventually affect whole body metabolism. This will have to be determined in 
future experiments where serum leptin and insulin levels, as well as tissue 
composition, can be assessed following 4-PBA ICV treatment. Although we have 
focused exclusively on the pancreas and brain for these studies, we must still 
consider the original model for T2D (Figure 1.1), in which several organs are 
interconnected in the manifestation of this disease state.  
Many questions still remain regarding the role of Sel1L and ERAD in 
glucose and energy homeostasis, especially at a molecular and mechanistic level. 
Do other factors contributing to diabetes and obesity, such as ageing, feature a 
downregulation of ERAD components in the pancreas and other peripheral 
organs? What is the interplay between ERAD, autophagy, and other UPR 
pathways in this condition of chronic ER stress? How is Sel1L regulated 
(transcriptional, translational, epigenetic) in normal and abnormal physiology? 
What other hormonal or developmental factors influence the expression of Sel1L 
and ERAD components in disease states? More specific to our mouse model, 
what are specific substrates of the Sel1L-ERAD machinery in each tissue? Or is 
pathogenesis the result of general ER stress in the absence of Sel1L? 
Candidate-gene studies and GWAS studies have greatly advanced our 
current understanding of the genetics of T2D. Together, several novel gene 
regions and variants that confer susceptibility to this disease have been 
identified. One gene, Potassium inwardly-rectifying channel, subfamily J, 
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member 11 (KCNJ11), encodes a channel with an important function in insulin 
secretion and is currently the target of the sulphonylurea class of drugs (210). 
Another, Peroxisome proliferator-activated receptor-$ (PPARG) encodes a 
transcription factor that is involved in adipocyte differentiation and is a target of 
the thiazodinedione class of drugs (211). The fat mass and obesity-associated 
gene (FTO) region has emerged as a commonly seen variation associated with fat 
mass (BMI) in the general population, but the mechanism is unknown (212). As 
mentioned previously (Chapter 4), SEL1L may be located within a locus 
associated with increased abdominal adiposity in obese individuals. Our 
research should encourage clinical and basic research scientists to further 
investigate and fine-map this region, especially in populations with a high 
prevalence of T2D (for example, South Asian and Mexican-American).  
It is increasingly clear that the UPR and ER stress have critical 
physiological and pathophysiological roles in β-cells and the hypothalamus. 
Although the mechanisms that cause organ dysfunction in T2D are variable and 
complex, a genetic predisposition is one of several key contributing factors. 
Elucidating the role of SEL1L and the overall understanding of ER stress in 
diabetes represents one step closer to the development of new clinical 
approaches in the treatment of this fatal and costly disease. Again, GWAS studies 
could substantiate SEL1L as a disease variant. Screening for SEL1L in patients 
with T2D could lead to a pharmacogenetic, personalized treatment. It is 
conceivable that drugs that can ameliorate existing ER stress, such as 4-PBA, 
would prove to be significant remedies for not only the symptoms of diabetes, 
but also the central cause of it. Additionally, targeted expression of ERAD 
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components to the pancreas or brain would facilitate protein processing and thus 
enhance secretion of insulin or MC4R. Finally, the generation of induced 
pluripotent stem cells and the clinical implementation of gene therapy are 
promising tools for translating our basic research into viable cures for T2D.   
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APPENDIX A 
Chapter 2 Supplemental Data 
 
a 
 
Confirmation of ER stress in HEK cells transfected with a plasmid encoding a 
truncated, dominant-negative Sel1L (DeltaCT) 
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APPENDIX B 
Chapter 3 Supplemental Data 
  a 
 
Confirmation of the β-cell-specific deletion (recombination) of Sel1L in tissues of 
Sellox/lox and Sellox/lox; RIP-Cre mice using genomic PCR 
 
 
     b 
 
Body weight of HFD-fed Sel1L+/+ and Sel1L+/- mice over the 28-week feeding 
period 
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      c 
 
Body weight of HFD-fed Sellox/lox, Sellox/+; RIP-Cre, and Sellox/lox; RIP-Cre mice over a 
14-week feeding period 
 
 
         d 
 
 
Insulin tolerance test (ITT) in Sellox/lox, Sellox/+; RIP-Cre, and Sellox/lox; RIP-Cre mice at 
6 weeks of age 
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        e 
 
 
Insulin tolerance test (ITT) in HFD-fed Sellox/lox and Sellox/lox; RIP-Cre mice after 10 
weeks on the diet 
 
  
         f 
 
  
Total pancreatic insulin content in HFD-fed Sel1L+/+ and Sel1L+/- mice after 20 
weeks on the diet 
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        g 
 
 
 
Total pancreatic insulin content in Sellox/lox and Sellox/lox; RIP-Cre mice at various 
ages and with HFD treatment 
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APPENDIX C 
Chapter 4 Supplemental Data 
a 
 
Confirmation of the hypothalamus-specific deletion (recombination) of Sel1L in 
Sellox/lox and Sellox/lox; RIP-Cre mice using genomic PCR 
 
          b 
 
 
 
Pair-feeding between the ages and 16 and 18 weeks for Sellox/lox and Sellox/lox; RIP-
Cre mice 
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        c 
 
  
Expression of Sel1L in various brain regions of Sellox/lox and Sellox/lox; RIP-Cre mice; 
ARC, arcuate; PVN, paraventricular nucleus; CTX, cortex; VMH, ventromedial 
hypothalamus; HIP, hippocampus; CB, cerebellum  
 
                d 
 
  
β-cell mass in Sellox/lox and Sellox/lox; RIP-Cre mice at 32 weeks of age, quantified by 
insulin staining of pancreatic sections 
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